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Abstract

Positive and Negative Modulatory Roles of Platelet Endothelial Cell Adhesion
Molecule-1 signaling in endothelial cell migration: coordination of Rho signaling
and targeting of SHP-2 tyrosine phosphatase activity

Dita Gratzinger

2003

Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1), an immunoglobulin
family adhesion molecule, is involved in endothelial migration and angiogenesis. I found
that PECAM-1 deficient endothelial cells exhibit enhanced nondirected single cell
motility and extension formation at the expense of wound-healing migration. These in
vitro endothelial behaviors model aspects of highly developmentally and
pathophysiologically relevant processes. Wound healing migration may model the
reendothelialization of denuded vasculature following balloon angioplasty or the
remodeling of vascular endothelium under variant flow conditions; single cell motility is
prominently involved in developmental processes such as endocardial-mesenchymal
transition within the cardiac cushion. A specific deficiency of RhoGTP in PECAM-1
deficient endothelial cells accounted for their migratory phenotype. The serum
sphingolipid sphingosine-1-phosphate (SIP) drives Rho-dependent migration and
angiogenesis. Indeed PECAM-1 proved necessary for an appropriate wound healing
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response to SIP. PECAM-1 localizes to rafts, and in its absence heterotrimeric G protein
components are differentially recruited to rafts, providing a potential mechanism for
PECAM-1-mediated coordination of SIP signaling.
PECAM-1 activates the tyrosine phosphatase SHP-2 via its phosphorylated
immunoreceptor tyrosine-based inhibitory motif (ITIM). ITEM signaling is not required
for the positive Rho-activating role of PECAM-1. Instead I found that ITIM signaling
retards wound healing migration, and that during migration the second ITIM tyrosine
becomes selectively dephosphorylated. The second ITIM tyrosine proved important for
recruitment but not activation of SHP-2. Any SHP-2 that remains transiently associated
with partially dephosphorylated PECAM-1 could in theory amplify the migration signal
by dephosphorylating adjacent PECAM-1 ITIMs. PECAM-1 also helps localize SHP-2
to the actin cytoskeleton, and to a subset of phosphoproteins. In fact, interfering with
PECAM-1 ITIM signaling not only increased wound healing migration but decreased
dephosphorylation of beta catenin and focal adhesion kinase. SHP-2 targeting is
instrumental in controlling endothelial wound healing migration, potentially via effects
on adherens junction stability and focal contact dynamics.
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Chapter 1: Background

PECAM-1 signaling in vascular biology

Platelet Endothelial Cell Adhesion Molecule-1, or PECAM-1, is a 130 kD type I
transmembrane adhesion molecule expressed on endothelial cells, platelets, neutrophils,
monocytes, and subsets of T cells (Albelda et al., 1991; Albelda et al., 1990; Newman et
al., 1990). Although PECAM-1 knockout (KO) mice are viable, fertile, and overtly
developmentally normal (Duncan et al., 1999), abnormalities of vascular functioning
become apparent in response to certain insults. Aberrant endothelial cell-platelet
thrombus interactions result in prolonged bleeding times attributable to endothelial rather
than platelet dysfunction (Mahooti et al., 2000). In a murine model of multiple sclerosis
(experimental autoimmune encephalitis) PECAM-1 KO mice exhibit neurologic deficits
early, and infiltration of their central nervous system by mononuclear cells is similarly
accelerated (Graesser et al., 2002). This abnormality too localizes to the vasculature
rather than the bone marrow; indeed these mice have a defect in restoration of junctional
integrity in response to a permeability-promoting stimulus.
In fact even angiogenesis is impaired in the PECAM-1 knockout mouse under
certain conditions. PECAM-1 deficient endothelial cells display poor tube formation in
three dimensional collagen culture. Moreover, a markedly diminished vascular
infiltration into a sterile polyvynil acetate sponge is seen in the PECAM-1 knockout
mouse during the chronic phase of a model of foreign body inflammation (Solowiej et al.,
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2002). PECAM-1 in fact plays multiple roles in vascular endothelial biology. AntiPECAM-1 antibodies block endothelial wound healing migration, whereas expression of
PECAM-1 mutated in its immunoreceptor tyrosine based inhibitory motif enhances
endothelial sheet migration (Cao et al., 2002; Kim et al., 1998). Treatment with
antibodies against PECAM-1 inhibits both endothelial tube formation and angiogenesis
(Cao et al., 2002; DeLisser et al., 1997).
PECAM-1 has roles to play in the physiology' of established vasculature as well.
Both anti-PECAM-1 treated wildtype endothelium and PECAM-1 deficient endothelium
has a defect in permeability to macromolecules (Ferrero et al., 1995; Graesser et al.,
2002). PECAM-1 may even play a role in regulation of vascular tone, with endothelial
PECAM-1 engagement mediating vasoactive mediator release, which may then act on
subjacent vascular smooth muscle cells (Gurubhagavatula et al., 1998). In the area of
leukocyte-endothelial interaction as well PECAM-1 has a role to play in leukocyte
adherence to (Chiba et al., 1999; Piali et al., 1995; Tanaka et al., 1992) and
transmigration across (Graesser et al., 2002; Gumina et al., 1996; Vaporciyan et al.,
1993) vascular endothelium.
The PECAM-1 extracellular domain consists of six immunoglobulin-like repeats
(Figure 1) and can mediate homophilic, and perhaps heterophilic, binding interactions
(Baldwin et al., 1994). The heterophilic binding partner for PECAM-1 remains unclear;
after initial reports of interaction with glycosaminoglycans (Vaporciyan et al., 1993), the
model of PECAM-1 as a heparin-binding protein has been effectively ruled out (Sun et
al., 1998). Interaction with CD38, an adenosine diphosphate ribosyl cyclase, (Deaglio et
al., 1998) has also been suggested, although no further work has been published to
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confirm this. PECAM-1 integrin heterophilic interactions, on the other hand, appear to
be real, if indirect; they generally involve an initial outside-in signaling step
experimentally induced by PECAM-1 engagement accompanied by tyrosine
phosphorylation of the cytoplasmic domain, followed by inside-out signaling in the form
of integrin activation (increased adhesive activity). This model holds for several families
of integrins including T cell 61 integrins (Tanaka et al., 1992), natural killer cell (52
integrins (Berman et al., 1996), and endothelial avp3 (Chiba et al., 1999).
The cytoplasmic domain of PECAM-1 has no intrinsic enzymatic activity but
instead associates with several signaling molecules including the tyrosine phosphatase
SHP-2, beta catenin, gamma catenin or plakoglobin, and STAT family proteins (Figure
1). The 106 residues of the PECAM-1 cytoplasmic domain are encoded by seven short
exons which are alternatively spliced during development (Baldwin et al., 1994; Sheibani
et al., 1999). Tyrosines 663 and 686 (Lu et al., 1997) in exons 13 and 14 constitute an
ITIM, or immunoreceptor tyrosine-based inhibitory motif (Newman, 1999), which binds
and modulates the activity of SH2-domain-containing proteins when phosphorylated
(Pumphrey et al., 1999).
Homophilic engagement of PECAM-1 using recombinant PECAM-1 extracellular
domain to mimic the cell-cell interactions found in confluent endothelium results in
tyrosine phosphorylation of the PECAM-1 cytoplasmic domain (Bird et al., 1999).
Antibody-mediated or homophilic PECAM-1 engagement independent of PECAM-1
clustering likewise causes src-dependent PECAM-1 tyrosine phosphorylation, resulting
in calcium influx and prostacyclin release (Gurubhagavatula et al., 1998; O'Brien et al.,
2001). PECAM-1 engagement-mediated integrin activation, on the other hand, requires
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concomitant PECAM-1 cis-dimerization or clustering (Leavesley et al., 1994; Tanaka et
al., 1992; Varon et al., 1998). PECAM-1 extracellular domains have been shown to cisdimerize with a dissociation constant of -12 |iM (Newton et al., 1999). Elegant studies
manipulating PECAM-1 cytoplasmic domain oligomerization state have validated the
model of PECAM-1-mediated inside-out signaling. Forced dimerization and
oligomerization of the PECAM-1 cytoplasmic domain caused changes in integrin
activation state and homophilic cell-cell adhesion (Zhao and Newman, 2001).
In addition to homophilic engagement, endothelial PECAM-1 is tyrosine
phosphorylated in response to a number of physiologic stimuli. Increased flow and
osmotic shock (Masuda et al., 1997); the atherosclerotic plaque component
lysophosphatidylcholine (Ochi et al., 1998); and exposure to vascular endothelial growth
factor (VEGF), a major angiogenic and permeability factor (Esser et al., 1998), all induce
PECAM-1 tyrosine phosphorylation. Phosphorylation is likely mediated by Src and/or
Csk family protein tyrosine kinases (Cao et al., 1998); in endothelial cells the protein
tyrosine phosphatase SHP-2 is a major binding partner at the phosphorylated PECAM-1
ITIM (Jackson et al., 1997; Masuda et al., 1997).
PECAM-1 also interacts with signaling proteins via other, as yet undefined
portions of its cytoplasmic domain. Endothelial PECAM-1 binds two armadillo family
proteins, beta catenin and plakoglobin, in a phosphorylation-regulated manner (Ilan et al.,
2000; Ilan et al., 1999). These intriguing signaling proteins shuttle between the plasma
membrane, where they link adherens junctions with the actin and the intermediate
filament cytoskeleton, respectively; the cytoplasm, where they are subject to degradation
via the proteasome pathway; and the nucleus, where they have transcriptional regulatory
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effects through interactions with LEF/TCF family transcription factors (Ben-Ze'ev and
Geiger, 1998).
PECAM-1 also binds and modulates the phosphorylation of STAT5a (Ilan et al.,
2001), a member of the family of signal transducers and activators of transcription. Like
the catenins, these multifunctional proteins shuttle between the plasma membrane and the
nucleus in a phosphorylation dependent manner to propagate transcriptional signals in
response to growth factor and cytokine signaling (Pellegrini and Dusantcr-Fourt, 1997).
In short, PECAM-1, while certainly involved in cell-cell interactions, is much more than
a simple adhesion molecule: it is a signaling scaffold sensitive to multiple physiologic
inputs and capable of coordinating complex endothelial behaviors.

5
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Figure 1: Schematic of Platelet-Endothelial Cell Adhesion Molecule-1.
Two adjacent endothelial cells with homophilically adhesive PECAM-1 molecules
and interacting signaling proteins are depicted. (Y = tyrosine, P = phospho)
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Research Aims

•

To characterize the positive role of Platelet Endothelial Cell
Adhesion Molecule-1 in the coordinated migration of
endothelial cells

•

To elucidate the signals and signaling pathways that
mediate this positive role

•

To clarify the negative modulatory role of the PECAM-1
immunoreceptor tyrosine-based inhibitory motif and its
interaction with the protein tyrosine phosphatase SHP-2 in
endothelial migration

7
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Chapter 2: PECAM-1 dependent migratory characteristics of endothelial cells

Summary

Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1), an immunoglobulin
family vascular adhesion molecule, is involved in endothelial cell migration and
angiogenesis (DeLisser et al., 1997; Lu et al., 1996). Endothelial cells lacking PECAM-1
expression exhibit increased single cell motility and extension formation. Their
coordinated wound healing migration is however retarded in comparison to PECAM-1
expressing endothelium. This migratory phenotype is reminiscent of cells in which Rho
activity has been suppressed by overexpressing a GTPase Activating Protein (Arthur et
al., 2000). The ability of PECAM-1 to restore wound healing migration to PECAM-1deficient cells was independent of both its extracellular domain and of signaling via its
immunoreceptor tyrosine-based inhibitory motif. PECAM-1-deficient endothelial cells
had a selective defect in RhoGTP loading, and inhibition of Rho activity mimicked the
PECAM-1-deficient phenotype of increased nondirected motility at the expense of
coordinated migration.
The wound healing advantage of PECAM-1-positive endothelial cells was not
only Rho-mediated but pertussis-toxin inhibitable. Both pertussis treatment (Lee et al.,
2000a) and inhibition of Rho-mediated signaling (Paik et al., 2001) likewise inhibits
wound healing migration mediated by the serum sphingolipid sphingosine-1-phosphate
(SIP), raising the question of whether PECAM-1 deficient endothelial cells would be
impaired in their coordinated wound healing migration response to SIP. Indeed the

8
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difference in wound-healing migration between PECAM-1 null and PECAM-l-positive
endothelial cells is minimized in sphingolipid-depleted media; moreover PECAM-1 null
endothelial cells fail to increase their migration in response to SIP.
Effective SIP-mediated endothelial migration requires coordinated signaling via
Galphai2 and Galphal3; these pathways are dysregulated in the absence of PECAM-1.
Signaling pathways downstream of Galphai2 such as ERK and FAK are inappropriately
activated even in non-migrating PECAIvI-i deficient endothelial ceils. Rho signaling,
which is downstream of Galphal3, is in contrast depressed in PECAM-1 null
endothelium. PECAM-1 localizes to caveolin-positive lipid raft domains and relative
recruitment of Galphai2 versus Galphal3 to rafts is decreased in PECAM-1-deficient
endothelial cells. PECAM-1 may thus support the effective SIP/RhoGTP signaling
required for wound healing endothelial migration by allowing for the spatially directed,
coordinated activation of Galpha signaling pathways.

9
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Introduction

PECAM-1 modulates migration in vitro and angiogenesis both in vitro and in
vivo. Transfection of non-endothelial cells has revealed a role for PECAM-1 in
modulating both coordinated, or wound healing, migration and single cell motility,
although results have been cell type-dependent PECAM-1 expression for example
inhibits coordinated migration in fibroblast (N1H/3T3) or epithelial (ECV304) cells (Kim
et al., 1998; Schimmenti et al., 1992). In mesothelial (REN) cells PECAM-1 instead
promotes coordinated migration and single cell motility (Cao et al., 2002). AntiPECAM-1 antibodies on the other hand block in vitro endothelial tube formation, wound
healing and single cell motility. PECAM-1 antibody treatment also retards angiogenesis
in multiple in vivo models, including FGF-2 (fibroblast growth factor-2) induced
angiogenesis, comeal neovascularization and tumor angiogenesis (Cao et al., 2002;
DeLisser et al., 1997).
The PECAM-1 knockout mouse is viable and fertile, with no evident angiogenic
or vasculogenic abnormalities at baseline (Duncan et al., 1999). However, defects in
angiogenesis into a polyvinyl acetate sponge are seen in a model of the chronic phase of
foreign body inflammation in the PECAM-1 knockout mouse, and endothelial cells
derived from the knockout mouse perform poorly in an in vitro assay of tube formation
(Solowiej et al., 2002). At the same time some aspects of endothelial cell motility are
enhanced in the absence of PECAM-1. In an in vitro model of cardiac cushion
development (Bemanke and Markwald, 1982), migration of individual endocardial cells
onto a type I collagen gel represents one step of the developmental process of epithelial-

10

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

mesenchymal transition (EMT). Exposure to high glucose interferes with endocardial
cell motility in this cardiac cushion explant model, secondary to a decrease in VEGFmediated signaling in hyperglycemic cultures. Single endocardial cell motility however
is preserved in the presence of high glucose in explants derived from the PECAM-1
knockout mouse (Enciso et al., 2003).
Rho family small G proteins act in a coordinated manner to regulate cell
extension formation, motility and directionality by modulating actin cytoskeletal and
focal contact dynamics. Rac promotes formation of immature focal complexes,
membrane ruffling, and lamellipodial extension formation. Rho then contributes to
adhesion during migration, with maturation of focal complexes into focal contacts and
suppression of further ruffling or focal complex formation (Nobes and Hall, 1999;
Rottner et al., 1999; Sastry and Burridge, 2000). The sequential activation of Rac and
suppression of Rho at the leading edge of a cell to promote lamellipodial protrusion is
followed by renewed Rho activation and firm focal contact adhesion to allow directed
forward cell movement.
Rho family small G proteins play prominent roles in vascular physiology, which
have recently been reviewed (van Nieuw Amerongen and van Hinsbergh, 2001).
Rearrangement and migration of confluent bovine aortic endothelial cells (BAECs) in
response to pulsatile flow is Rho-dependent (Yano et al., 1996), as is coordinated, wound
healing migration of human umbilical vein endothelial cells or HUVEC (Aepfelbacher et
al., 1997). Rho signaling is likewise required for HUVEC tube formation in vitro and
VEGF-induced chorioallantoic membrane angiogenesis and tumor angiogenesis in vivo
(Uchida et al., 2000). In fact therapeutic levels of HMG-CoA (3-hydroxy-3-
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methylglutaiyl coenzyme A) reductase inhibitors, statin compounds which interfere with
cholesterol synthesis, block tube formation and angiogenesis by blocking the
geranylgeranylation of Rho (Park et al., 2002a).
Sphingosine-1-phosphate (SIP) is a platelet-released lipid mediator of endothelial
chemotaxis, wound-healing endothelial migration, angiogenesis, and vascular maturation
(English et al., 2001). Platelets phosphorylate sphingosine and store the resulting SIP
(Fukuhara et al., 1999). Platelet-released SIP accounts for most of the chemotactic
activity of serum; SIP isolated from serum supports chemotaxis and FGF-2-induced
angiogenesis (English et al., 2000) SIP signals through Endothelial Differentiation Gene
(EDG) seven-transmembrane receptors to mediate endothelial cell migration and
angiogenesis through heterotrimeric G-protein signaling (Lee et al., 2000a; Lee et al.,
1998; Lee et al., 1999b). SIP signaling via EDG-1 activates Galphai2, localizing and
activating focal contact components Focal Adhesion Kinase (FAK) and src at the leading
edge to promote lamellipodial extension formation (Rosenfeldt et al., 2001). EDG-3
meanwhile activates Galphal3 to appropriately remodel the actin cytoskeleton and
strengthen focal contacts via Rho signaling, allowing coordinated migration to occur
(Buhl et al., 1995; Offermanns et al., 1997; Paik et aL, 2001).
Endothelial caveolin-rich membrane subdomains, or caveolae, represent a subset
of low density, cholesterol-enriched lipid rafts (Sowa et al., 2001). These caveolinpositive rafts are enriched for certain signaling proteins, including heterotrimeric G
proteins as well as Src family kinases and many others (Lisanti et al., 1994). Caveolin
family proteins act as scaffolds which associate with signaling proteins and modulate
their activity (Galbiati et al., 2001). In particular, caveolin-1 negatively regulates
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heterotrimeric G protein signaling by preferentially binding inactive, GDP (guanosine
diphosphate)-bound Galpha proteins and inhibiting the GDP/GTP (guanosine
triphosphate) exchange that would reactivate them (Li et al., 1995). EDG-1 too is
recruited to lipid rafts in response to SIP treatment, and according to one report, EDGreceptor-mediated signaling may be inhibited by interaction with caveolin-1 (Igarashi and
Michel, 2000). I have therefore examined the role of PECAM-1 in promoting S1P-EDGdriven coordinated wound-healing migration over nondirected motility of individual
endothelial cells via modulation of Rho signaling.
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Results
Immortalized PECAM-1 deficient and reconstituted endothelial cells

In order to efficiently explore the role of PECAM-1 in endothelial migration I
needed a model system of matched PECAM-1 null and PECAM-1 expressing endothelial
cells that would survive through multiple passages and tolerate multiple manipulations.
It is possible to isolate primary mouse endothelial cells from PECAM-1 knockout and
wildtype animals, but the procedure is time-consuming and difficult and the resulting
endothelial cells last for very few passages in culture. An immortalized lung endothelial
cell line has been derived from the PECAM-1 knockout mouse (PecamKO). This line
has also been reconstituted with full-length PECAM-1 (PecamRC) to provide a control
immortalized line resembling wildtype, PECAM-1 expressing endothelium (Graesser et
al., 2002; Wong et al., 2000).
I confirmed PECAM-1 surface expression levels and maintenance of endothelial
cell markers by fluorescence activated cell sorting (FACS) analysis (Figure 2). A mouse
hemangioendothelioma-derived cell line (Eoma) which maintains characteristics of
microvascular endothelial cells (Obeso et al., 1990) was used as a positive control.
FACS analysis revealed no PECAM-1 expression in PecamKO endothelial cells, as
expected. PecamRC endothelial cells have surface levels of PECAM-1 similar to those in
the Eoma positive control. Both PecamRC and PecamKO endothelial cell lines maintain
expression of the endothelial marker VE-cadherin.
PecamRC endothelial cells form the cobblestone-like monolayers typical of
endothelial cells in culture. PecamKO endothelial cells form similar tightly compact

14

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

monolayers, but the cells are more spindle-shaped. Figure 3a demonstrates this
morphology at the migrating front of a wound-healing endothelial monolayer. These
morphologic differences are seen more clearly in individually plated cells that have been
allowed to spread on fibronectin. Individually plated PecamKO cells form multiple
extensions whereas PecamRC cells spread more evenly (Figure 3b). As a surrogate
measure of extension formation or deviation from circularity, I derived theoretical radii
(r) from the measured perimeter and the measured area, respectively, as if they had been
perfect circles. For a perfect circle the ratio of rpenmeter to rarea will be 1.0; any deviation
from circularity will produce higher ratios. This number is dimensionless and therefore
independent of any variation in size between cell populations. The ratio of rpenmeter to rarea
is in fact significantly increased in PecamKO cells, confirming the apparent increase in
extension formation seen when cells are individually plated (Figure 4).
Given the morphological differences between PecamKO and PecamRC
endothelial cells, I next assessed them for gross differences in actin cytoskeletal
architecture and focal contact or adhesion formation (Figure 5). Cells were cultured on
fibronectin-coated slides, then fixed and stained with rhodamine-conjugated phalloidin to
visualize filamentous or F-actin and with anti-phosphopaxillin to highlight focal contacts
and adhesions (Nakamura et al., 2000). Phalloidin staining revealed stress fibers
throughout the cytoplasm of PecamRC cells, as compared to sparser, cortical actin bands
in PecamKO cells. Immunostaining for phosphopaxillin revealed typical elongated focal
adhesions in PecamRC cells; in PecamKO cells, phosphopaxillin staining prominently
highlighted the leading edges of lamellipodial extensions, sites of newly forming focal
complexes and contacts (Parsons et al., 2000).
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Figure 2: FACS analysis of PecamRC and PecamKO cells.
Surface expression o f PECAM-1 is absent in PecamKO cells; the level of expression
on PecamRC cells is similar to that in Eoma cells. Surface expression o f endothelial
marker VE-cadherin on both PecamRC and PecamKO cells is similar to that in
Eoma cells, (control = secondary antibody)
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Figure 3: Morphology of PecamRC and PecamKO endothelial cells.
A. Confluent endothelial cells were scraped, then allowed to migrate for 24 hours.
B. Cells were allowed to spread for four hours, fixed and stained with crystal violet.
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Figure 4: Extension formation is increased in the absence of PECAM-1.
Quantitation of ratios of r derived from perimeter versus r derived from area
as a measure of the deviation from circularity confirms significantly higher
extension formation by PecamKO cells. (* p < 0.000000005 vs RC, n = 89)
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Figure 5: Cytoskeletal and focal contact immunostaining.
Immunofluorescence demonstrates rounded cell shape and increased stress fibers in
PecamRC cells (upper left panel, phalloidin stain) and distinct dash-like focal
adhesion contacts with the underlying fibronectin matrix (upper right panel, antiphosphopaxillin stain). PecamKO cells exhibit sparse cortical actin staining (lower
left panel) and extensions whose leading edges are highlighted with the focal contact
component phosphopaxillin (lower right panel).
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PECAM-1 promotes wound-healing migration over nondirected motility

I set out to address the role of PECAM-1 in two aspects of endothelial cell
motility: the intrinsic nondirected movement of individual cells, and the coordinated
movement of endothelial monolayers. Nondirected cell motility, or chemokinesis, was
assessed by quantitating the cells that had reached the underside of a fibronectin-coated 8
pm pore Transweii® membrane 2.5 hours after plating on top of the membrane. There
was no chemotactic or haptotactic stimulus involved in this assay: the membranes were
fibronectin coated on both sides, and no additional growth factors were added to the
serum-containing media on either side of the membrane. Coordinated migration of
endothelial cells was assessed using a wound-healing assay: endothelial cells were
allowed to reach confluence on a fibronectin-coated culture dish, then scraped to leave
alternating cell-free areas in a bull’s eye pattern. The distance migrated by the leading
edge of monolayer cells into the scraped wound was measured after 24 hours.
Previous studies have come to conflicting conclusions about the effect of
PECAM-1 expression on migration. Ectopic expression of PECAM-1 has been reported
to decrease wound-healing migration in epithelial cells (Schimmenti et aL, 1992) on the
one hand, and to increase both wound-healing and nondirected motility in mesothelial
cells (Cao et al., 2002) on the other. In endothelial cells, where PECAM-1 expression is
physiologic, the role of PECAM-1 in the two types of migration turns out to be
discordant. I found that PecamKO endothelial cells have significantly enhanced
nondirected motility (Figure 6a) but decreased wound-healing migration (Figure 6b) as
compared to PecamRC endothelial cells.
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To rule out the possibility that decreased wound healing in PecamKO cells is
secondary to a proliferation rather than a migration defect, the wound healing assay was
also carried out in the presence of mitomycin C to block proliferation (Figure 6b). A
concentration of mitomycin C that blocked the appearance of all mitotic figures as
visualized by DAPI staining but that was minimally toxic was determined empirically
(data not shown). Proliferation does contribute to wound healing migration, and overall
distance migrated during mitomycin C treatment dropped by -50% for both PecamRC
and PecamKO endothelial cells. However the differential in migration between the two
cell types remained, implying that a proliferation defect does not account for the
retardation of wound healing migration in PECAM-1-deficient endothelial cells.
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Figure 6: Migration characteristics of PecamKO and PecamRC cells.
A. PecamKO cells display enhanced nondirected motility through 8 pm fibronectin
coated membranes but B. poor wound-healing migration on fibronectin in the 24 hour
scrape assay as compared to PecamRC cells. The wound migration defect was not
eliminated by blocking proliferation with mitomycin C (mito C). (* p < 0.0005 vs
PecamRC; n = 8 for wound healing; n = 9 for transmigration)
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Parsing the contribution of PECAM-1 to wound healing

The PecamKO and PecamRC endothelial cells I have used to characterize the role
of PECAM-1 in endothelial migration have been easy to work with largely because they
are immortalized. By the same token, however, immortalization with polyoma middle T
antigen is known to affect signaling through multiple pathways (Wagner and Risau,
1994), many of which could affect migration as well as survival and proliferation. To
rule out the possibility that the migration differences between PecamKO and PecamRC
were due to the interaction of PECAM-1 with ectopically expressed polyoma middle T
antigen rather than to the expression of PECAM-1 itself, I chose to confirm our findings
in a primary endothelial cell line.
I used antisense oligonucleotides (Baker et al., 2001) to decrease PECAM-1
expression in human umbilical vein endothelial cells (HUVEC). Western blotting
analysis confirmed stable depletion of PECAM-1 protein at both 24 and 48 hours in
HUVEC treated with antisense oligonucleotide, as compared to stable PECAM-1
expression in HUVEC treated with the scrambled oligonucleotide control (Figure 7a).
Nondirected motility was significantly increased and wound healing migration decreased
in PECAM-1 depleted HUVEC as opposed to control oligonucleotide treated HUVEC
(Figure 7b), supporting the role of PECAM-1 itself in modulating endothelial migratory
behavior. The fact that a similar phenotype was seen in primary endothelial cells derived
from human as opposed to murine tissue, and from a macrovascular umbilical vein bed as
opposed to a microvascular lung vascular bed, confirmed the wider applicability of the
findings in PecamKO and PecamRC endothelial cells.
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I next set out to ascertain which domains of PECAM-1 were needed to mediate its
positive role in wound healing migration. The effect of PECAM-1 on wound-healing
could simply involve the ectodomain, which mediates homophilic cell-cell interactions.
It might involve outside in and inside out signaling via both the ectodomain and the
cytoplasmic domain by modulating integrin activation, with engagement and clustering
of the ectodomain leading to signaling via tyrosine phosphorylation of the PECAM-1
ITiM (Chiba et al., 1999; Sun et al., 1996). The ITIM domain becomes
dephosphorylated during wound healing migration (Lu et al., 1996) but phosphorylated
during flow-induced rearrangement (Osawa et al., 1997), modulating binding and
activation of SH2-domain containing proteins, and has been the principal target of studies
o f PECAM-1 mediated signaling to date. This signaling modality can be inactivated
through site-specific mutagenesis of the tyrosines within the PECAM-1 ITIM.
Alternately, the role of PECAM-1 in wound healing may call on neither the ITIM nor the
ectodomain, but instead may involve signaling via other portions of the cytoplasmic
domain and through interacting signaling proteins, known or unknown.
To determine the relative contributions of each domain of PECAM-1 to
endothelial wound-healing migration, I expressed three different PECAM-1 constructs in
originally PECAM-1 deficient endothelial cells. PecamKO cells were transiently
transfected with constructs encoding either full-length, wildtype PECAM-1; wildtype
PECAM-1 lacking its ectodomain; or PECAM-1 mutated in its ITIM domain to eliminate
phosphorylation (Figure 8a). At 24 hours post transfection the endothelial cells were
replated to fibronectin-coated dishes, allowed to become confluent overnight, and then
assessed for their wound healing ability.

24

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Unlike control transfection with green fluorescent protein (GFP) or vascular cell
adhesion molecule (VCAM), transfection of full-length PECAM-1 restored wound
healing migration to PecamKO cells (Figure 8b). In fact all three PECAM-1 constructs
were equally capable of supporting wound healing migration. Absolute rates of
migration between transfection and nontransfection experiments are not comparable,
since the toxicity of the transfection itself decreases wound healing migration.
Nevertheless the degree of rescue of wound healing with any of die PECAM-i constructs
of -60% roughly approximates the -50% wound healing advantage of PecamRC versus
PecamKO endothelial cells. Thus neither the ectodomain nor the intact ITIM domain is
required to confer the PECAM-mediated wound-healing advantage. The PECAM-1
cytoplasmic domain itself appears to signal to modulate wound healing migration
independent of tyrosine phosphorylation-mediated recruitment of SH2-domain containing
proteins. Further truncation mutant transfection experiments will be necessary to localize
the responsible portion of the PECAM-1 cytoplasmic domain.
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Figure 7: PECAM-1 expression modulates endothelial migration.
A. Antisense oligonucleotides decrease PECAM-1 expression in HUVEC as compared to
the scrambled oligonucleotide control.
B. Antisense-treated HUVEC have significantly increased motility but decreased wound
healing migration (* p < 0.005 vs scrambled; n = 6 for wound healing; n = 9 for motility)
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Figure 8: Contribution of PECAM-1 domains to wound healing.
A. The constructs used in transient transfections of PecamKO endothelial cells include
full-length PECAM-1 (FL), PECAM-1 mutated in its ITIM domain (2F), and PECAM-1
lacking the ectodomain (Tr).
B. Transient transfection of PecamKO with FL, 2F, and Tr PECAM-1 contstructs but not
with GFP or VCAM restores wound healing migration to PecamKO cells.
(* p < 0.0005 vs GFP; n = 8)
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PECAM-l-nuU endothelial cells are selectively deficient in RhoGTP

PecamKO endothelial cells show pronounced extension-formation and enhanced
nondirected motility, but blunted wound-healing migration. Lamellipodia are RacGTPdriven membrane extensions (Nobes and Hall, 1999) involved in initiation of cell
motility. Endothelial wound healing in contrast is RhoGTP-mediated and is sensitive to
inhibition of Rho signaling (Aepfel'bacher et aL, 1997). The two-sided migratory
phenotype of PECAM-1 null endothelial cells may thus reflect an imbalance of Rho and
Rac signaling. I used selective pulldown assays to assess levels of activated or GTPbound Rho and Rac. RhoGTP was pulled down with a recombinant GST (glutathione-Stransferase) - Rhotekin Rho binding domain fusion protein (Ren and Schwartz, 2000).
GST-p21 Activated Kinase (PAK) Rac binding domain fusion protein was used for
RacGTP pulldowns (Royal et al., 2000). Glutathione agarose-bound fusion protein was
used to selectively pull down GTP-bound Rho or Rac from whole cell lysates; the pulled
down protein was quantitated and normalized to total G protein expression.
PecamKO endothelial cells proved to have a> 50% deficiency in RhoGTP levels
as compared to Pecam RC endothelial cells (Figure 9a). There was by comparison no
significant difference between the two cell types in RacGTP loading (Figure 9b). Lack
of PECAM-1 expression in endothelial cells thus upsets the balance of small G protein
signaling, with normal levels of Rac activation and concomitant decreased Rho signaling.
The balance appears to tilt in favor of Rac-mediated control of actin cytoskeletal and
focal contact dynamics, lowering the threshold for Rac-mediated extension formation and
motility while interfering with Rho-dependent wound healing migration.
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The trio o f well-studied small G proteins involved in modulation of actin
cytoskeletal and focal contact dynamics in cell motility include not only Rho and Rac but
also Cdc42. Cdc42 appears to cooperate with or act upstream of Rac in the initiation of
extension formation in the form of membrane ruffling and lamellipodial protrusions
(Clark et al., 1998; Nobes and Hall, 1999). The PAK binding domain fusion protein
should pull down the GTP-bound form of the related small G protein Cdc42 in addition
to GTP-bound Rac; however I was never able to detect Cdc42 in the pulldown fraction,
whether due to the small fraction of activated Cdc42 present in these cell lysates or due to
technical difficulties. Thus any potential additional role for Cdc42 in preferentially
promoting extension formation in PecamKO cells in concert with Rac remains to be
evaluated.
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Figure 9: PecamKO cells have a selective defect in RhoGTP loading.
A. Pulldowns with the recombinant RhoGTP-binding domain of Rhotekin reveal
significantly decreased levels of RhoGTP in PecamKO cells (* p < 0.05 vs PecamRC)
B. Pulldowns with the recombinant RacGTP binding domain of PAK reveal no
difference in RacGTP loading in PecamRC vs PecamKO cells (shown in duplicate).
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Activation of p!90RhoGAP contributes to RhoGTP deficiency

RhoGTP levels during migration are regulated by a GTPase activating protein, or
GAP, which promotes the dephosphorylation of Rho-bound GTP to GDP and
consequently inhibits Rho-mediated signaling. pl90RhoGAP was cloned and
characterized as a pl20RasGAP-associated protein which colocalizes with alpha5betal
integrin and Rho upon integrin clustering (Burbelo et al., 1995). The importance of
pi 90RhoGAP in directed migration became evident with the generation of the
pl90RhoGAP knockout mouse, which has a severe neural morphogenetic defect and
excessive filamentous actin (F-actin) accumulation indicative of hyperactive RhoGTP
signaling (Brouns et al., 2000).
pl90RhoGAP inhibits Rho signaling upon integrin engagement in a srcdependent manner (Arthur et aL, 2000), disinhibiting extension formation and cell
motility (Arthur and Burridge, 2001). Figure 10a provides a schematic of src-mediated
pi 90RhoGAP activation. Src-mediated tyrosine phosphorylation of pi 90RhoGAP
mediates association with pl20RasGAP via its SH2 domains. This association in turn
promotes the GTPase activity of pl90RhoGAP toward RhoGTP (Haskell et al., 2001).
The consequent depression of local RhoGTP-mediated signaling then promotes extension
formation and initiation of directed wound healing migration (Kulkami et al., 2000).
Low molecular weight protein tyrosine phosphatase (LMW-PTP) dephosphorylates
pl90RhoGAP, blocking its inhibition of Rho signaling (Raugei et al., 2002).
To determine whether the low baseline levels of RhoGTP in PECAM-1 deficient
endothelial cells are at least partly attributable to increased activation of pl90RhoGAP,
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pl20RasGAP was immunoprecipitated to determine levels and tyrosine phosphorylation
of associated pi 90RhoGAP. Quantitation revealed significantly increased association of
pl20RasGAP with pl90RhoGAP in PecamKO as compared to PecamRC endothelial
cells (Figure 10b). The tyrosine phosphorylation of that associated pl90RhoGAP was
also significantly increased. In the converse experiment immunoprecipitation of
pl90RhoGAP also revealed increased p i90 tyrosine phosphorylation and pl20RasGAP
association (data not shown). These findings are consistent with increased pl90RhoGAP
activity and may in part account for the observed decrease in RhoGTP levels in
PecamKO endothelial cells.
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Figure 10: RhoGTP regulation by pl90RhoGAP.
A. The ability of pl90RhoGAP to inhibit Rho signaling is regulated by its tyrosine
phosphorylation (PY) and association with pl20RasGAP.
B. Immunoprecipitation (IP) of pl20RasGAP reveals higher association with pl90
RhoGAP (first two columns) and increased PY of that pl90RhoGAP (second two
columns) in PecamKO cells (* p < 0.05 vs PecamRC).
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RhoGTP deficiency mimics the PECAM-1 null motility phenotype

PecaxnKO endothelial cells, then, are selectively deficient in RhoGTP, and excess
tyrosine phosphorylation of pl90RhoGAP and association with pl20RasGAP may at
least in part account for this deficiency. Furthermore, the divergent migratory
characteristics of PECAM-1 deficient endothelial cells, including increased extension
formation and nondirected single ceil motility as opposed to decreased coordinated
wound healing migration, are consistent with depressed Rho signaling, as when
pl90RhoGAP is overexpressed (Arthur et aL, 2000). To determine whether in fact
decreased Rho activity accounts for the migration characteristics of PecamKO endothelial
cells, the Rho signaling pathway was blocked at the level of Rho itself and of its effector
p i 60 Rho coiled-coil kinase, or pl60ROCK, which mediates the RhoGTP-induced
increase in stress fibers and focal adhesions (Ishizaki et al., 1997).
The C3 exoenzyme of C. botulinum (exoC3) ADP-ribosylates Rho and directly
inhibits its activity, interfering with endothelial migration (Aepfelbacher et aL, 1997).
ExoC3 abrogated the wound-healing advantage of PecamRC as compared to Pecam KO
endothelial cells (Figure 11a). Moreover, it actually significantly increased nondirected
endothelial cell motility (Figure lib ). Y27632 is a synthetic inhibitor of the Rho
effector pl60ROCK, which inhibits endothelial tube formation in vitro and angiogenesis
in vivo (Uchida et al., 2000). Y27632 had effects similar to those of ExoC3 in PecamKO
and PecamRC cells, with increased nondirected cell motility at the expense of diminished
coordinated wound healing migration (Figure 12).
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PECAM-1 deficient endothelial cells exhibit increased extension formation to
parallel their increased nondirected single cell motility. Quantitation of rpcnmeter to r ^
ratios confirmed that extension formation was also significantly increased upon inhibition
o f Rho signaling (Figure 13a). Hence decreased basal RhoGTP levels can account for
both the migratory and the morphologic characteristics of the PecamKO endothelial cell
phenotype. To reaffirm that Rho signaling levels are important determinants of
endothelial motility in general, I assessed the effect of Y27632 on primary bovine aortic
endothelial cells (BAECs). Inhibition of pl60ROCK significantly increased both
nondirected motility and extension formation in BAECs, confirming the general
applicability of these findings to endothelial cell behavior (Figure 13b).
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Figure 11: Rho inhibition mimics the PecamKO migratory phenotype.
Cells were treated with exoC3 to directly inactivate Rho.
A. Wound migration was significantly inhibited and B. nondirected motility was
significantly promoted by exoC3 treatment. (* p < 0.005 vs PecamRC control;
n = 8 for wound healing; n = 9 for motility)
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Figure 12: pl60ROCK inhibition resembles Rho inhibition.
Cells were treated with Y27632 to inactivate pl60ROCK.
A. Wound migration was significantly inhibited and B. nondirected motility was
significantly promoted by Y27632 treatment (* p < 0.005 vs PecamRC control;
n = 8 for wound healing; n = 9 for motility)
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Figure 13: Rho signaling inhibits endothelial extension formation.
A. Quantitation of ratios of r derived from perimeter versus r derived from area
as a measure of the deviation from circularity confirms that extension formation
was significantly increased in Y27632-treated cells.
B. BAECs respond to inhibition of Rho signaling with increased nondirected motility and
extensions. (* p < 0.005 vs untreated control; n = 9 for motility; n = 98 for extensions)
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PECAM-1 confers sensitivity of single cell motility to high glucose

Children of diabetic mothers are at increased risk for heart defects, particularly
defects of the outflow tract and atrioventricular septum (Loffredo et al., 2001). Many of
these can be traced to incomplete epithelial-mesenchymal transformation (EMT) within
the endocardial cushion. Individual endocardial cells in this thickened area of the cardiac
lube migrate down into the underlying cardiac jelly. They assume a mesenchymal
phenotype and contribute to the incipient atrial and ventricular membranous septae and
atrioventricular valves. In a model of EMT using the explanted murine endocardial
cushion (Bemanke and Markwald, 1982), endocardial cells initially spread out from the
explant as an endothelioid sheet They then disperse out over the type I collagen gel
substrate as they take on an elongated, fibroblast-like morphology, gain expression of
mesenchymal markers such as alpha smooth muscle actin, and lose expression of
endothelial markers including PECAM-1.
Previous work from our lab has demonstrated that culturing endocardial cushion
explants under conditions of increased glucose concentration, at levels similar to those
found in poorly controlled maternal diabetes, interferes with EMT. Single cell motility is
blocked; endocardial cells instead continue to grow out as a PECAM-1 positive, alpha
smooth muscle actin negative endothelioid sheet. Endocardial cells originating from the
PECAM-1 knockout mouse however are resistant to this effect: they continue to disperse
out as individual cells even in the presence of high glucose (Enciso et a l, 2003).
PECAM-1-deficient endocardial cells, then, are resistant to inhibition of single
cell motility by high glucose. Given our findings of increased nondirected motility in
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PECAM-1-deficient endothelial cells, I asked whether cultured endothelial cells could
model this physiologically relevant behavior. Endothelial culture media contains 5 mM
glucose, which approximates euglycemia. The nondirected motility of endothelial cells
was determined in the presence of 30 mM glucose, a concentration consistent with
poorly-controlled diabetes mellitus. I found that PecamRC endothelial cells were indeed
retarded in their motility in the presence of high glucose as compared to a mannose
osmotic control (Figure 14). However, as had been the case in the cardiac cushion
culture system, the motility of PecamKO cells was unaffected by high glucose. Thus the
behavior of endothelial cells in culture faithfully mirrors the behavior of explanted
endocardial cushion tissue, and may provide useftd starting points for modeling complex
vascular behaviors.
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Figure 14: PecamKO cells resist glucose-mediated retardation of motility.
On both collagen A. and on fibronectin B. endothelial cell motility is significantly
decreased in the presence of high glucose as compared to mannose osmotic control
(* p < 0.005 vs mannose, n = 9). PecamKO cells are resistant to the glucose effect.
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Decreased Rho signaling provides resistance to high glucose

Having determined that endothelial cell motility models the behavior of
endocardial cells in the cardiac cushion explant assay, I determined to explore a potential
mechanism for the resistance of PECAM-1 null endocardial cells to inhibition of their
motility. The glucose-mediated inhibition of endocardial cell motility is attributable to
decreased expression of Vascular Endothelial Growth Factor (VEGF). Normoglycemic
cultures depleted of VEGF exhibit a migratory phenotype very similar to that of
endocardial cushions cultured in the presence of high glucose. Conversely, VEGF
supplementation is sufficient to rescue single cell motility in high glucose cardiac cushion
cultures (Enciso et aL, 2003). The correct balance and timing of VEGF signaling appears
to be crucial for successful endocardial cushion development: too much VEGF too early
has likewise been shown to inhibit EMT (Dor et al., 2001).
Interestingly, VEGF-mediated endothelial motility is Rac-mediated and is
inhibited by a constitutively-active mutant of Rho (Soga et al., 2001). I therefore
hypothesized that the resistance of PECAM-1-deficient endocardial cells to glucosemediated retardation of single cell motility is secondary to low Rho activation levels at
baseline, with a consequent disinhibition of Rac-mediated lamellipodial extension and
nondirected motility. To determine whether the decreased sensitivity of PECAM-1deficient cells to glucose-mediated retardation could in fact be attributed to their
decreased Rho activation at baseline, I quantitated endothelial cell motility in the
presence of glucose plus or minus the pl60ROCK inhibitor, Y27632, to block signaling
downstream of Rho. Indeed, concomitant treatment with Y27632 blocked the effect of
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high glucose on motility in PecamRC cells (Figure 15a). Two way analysis of variance
(ANOVA) revealed a significant cell type by treatment effect for high glucose which was
abrogated by inhibition of the Rho effector pathway with Y27632. The ANOCA results
in effect confirm that the migratory response of PecamRC cells and PecamKO cells to
high glucose is significantly different, and that this differential response requires intact
signaling via the Rho effector pathway.
VEGF signaling in endothelial cells is mediated by Rac signaling and production
of reactive oxygen species (ROS) (Colavitti et al., 2002). Figure 15b presents a model of
VEGF-mediated induction of Rac-mediated motility, and inhibition of that motility by
way of the PECAM-1-dependent stimulation of basal Rho activity. The small GTPase
Rac contains an insert region which contributes to the production of ROS in the form of
hydrogen peroxide (H2 O2 ) (Deshpande et al., 2000); this region is required for
lamellipodial induction (Kamoub et al., 2001). LMW-PTP, the low molecular weight
protein tyrosine phosphatase which dephosphorylates pl90RhoGAP (Figure 10a),
promotes Rho signaling by blocking the dephosphoiylation of Rho-associated GTP
(Raugei et al., 2002). In fact overexpression of a human isozyme of LMW-PTP has been
shown to block VEGF-mediated endothelial migration and angiogenesis (Huang et al.,
1999). LMW-PTP is physiologically inhibited by H2 O2 , which oxidizes two active site
cysteine residues to form a disulfide bond (Caselli et al., 1998), providing a likely
mechanism for local Rac-mediated inhibition of Rho signaling.
Thus VEGF-mediated signaling acts to promote extension formation and initiate
motility by locally inhibiting RhoGTP. The major source of VEGF during endocardial
cushion morphogenesis appears to be the layer of myocardium underlying the cardiac
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jelly (Enciso et al., 2003). This localized RhoGTP inhibition likely serves to direct
endocardial cells down into the cardiac jelly, where they will go on to contribute to the
incipient atrioventricular septum and valves. The low baseline levels of RhoGTP in
PECAM-1 deficient endothelial or endocardial cells should therefore lower the barrier for
Rac-mediated initiation of single cell motility. Lowering the threshold for motility,
however, must by definition come at the cost of losing sensitivity to directional
information, due to a lowered signal to noise ratio for initiation of extension formation.
This lowering of die barrier for Rac-mediated extension formation in turn potentially
explains the robust nondirectional single cell motility of PECAM-1 deficient cells in the
face of decreased VEGF-Rac signaling secondary to hyperglycemia.
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Figure 15: Inhibition of Rho signaling abrogates the effect of glucose on motility.
A. Treatment with the pl60ROCK inhibitor Y27632 blocks the inhibitory effect of
glucose on motility. Two way ANOVA reveals a significant cell type by treatment effect
(p < 0.0005) for glucose, which is abrogated in the presence of Y27632.
B. Induction of lamellipodial extension through repression of Rho signaling.

45

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

PECAM-1 is required for effective Galphai2-mediated signaling

SIP, a serum sphingolipid, signals through heterotrimeric G proteins associated
with its seven-transmembrane EDG-family receptors. SIP-mediated endothelial woundhealing and directed migration is both Rho-dependent (Figure 11) and pertussis toxin
(PTX) inhibitable. Pertussis toxin subunit A inhibits signaling via heterotrimeric G
proteins by catalyzing ADP ribosyiation and inactivation of Gaiphai family subunits,
including Galphai2, downstream of EDG-1 (Lee et al., 1996). SIP signaling via EDG-1
and EDG-3 potentiates capillary morphogenesis, adherens junction formation, and
angiogenesis in a Rho-dependent and pertussis toxin-inhibitable manner (Lee et al.,
1999a). SIP-induced endothelial tube formation and matrigel plug angiogenesis (Lee et
al., 1999b) as well as wound healing migration (Lee et aL, 2000a) and directed,
chemotactic motility (Lee et al., 2000b; Liu et al., 2001) have all been shown to be PTXinhibitable as well.
SIP is one of an array of signaling molecules, including chemokines such as
stromal derived factor-1 (SDF-1) (Salvucci et al., 2002) as well as thrombin
(Maragoudakis et al., 2002), that promote endothelial migration and angiogenesis through
heterotrimeric G protein signaling. Defects in heterotrimeric G protein signaling
downstream of SIP may therefore be representative of dysfunctional responses to a broad
array of seven-transmembrane receptor mediated signals in PECAM-1 deficient
endothelial cells. Given the Rho-dependence of PECAM-1-mediated endothelial wound
healing migration, I set out to see whether this effect might in part reflect modulation
heterotrimeric G protein signaling by PECAM-1. Indeed, I found that PTX treatment
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abrogated the wound-healing advantage of PecamRC cells; no significant difference in
distance migrated remained between PTX-treated PecamRC and PecamKO endothelial
cells (Figure 16a). This, together with the key role of Rho signaling in the wound
healing advantage conferred by PECAM-1, strongly implicates a dysfunction in
heterotrimeric G protein-mediated signaling in the migratory phenotype of PECAM-1
null endothelial cells.
PTX inhibits Gaiphai2-mediated activation of Extracellular signal Regulated
Kinase (ERK) (Lee et al., 1996) and FAK as well as src (Liu et al., 2000; Rosenfeldt et
al., 2001) downstream of the EDG-1 receptor (Figure 16b). To uncover potential
disturbances in Galphai2-mediated signaling in PecamKO endothelial cells, I performed
Western blots with phosphospecific antibodies to threonine/tyrosine phosphorylated ERK
and to tyrosine 397-phosphorylated FAK (FAK PY397). These revealed significantly
increased activation of both ERK signaling and of FAK PY397 in confluent PecamKO
endothelial cells as compared to PecamRC cells (Figure 17). ERK phosphorylation is
normally increased only at the free edge of an endothelial monolayer as a part of the
normal migratory response to mechanical wounding (Pintucci et al., 2002). Indeed, ERK
phosphorylation increased as expected in wounded, migrating PecamRC monolayers,
while no further increase was observed in the already high levels of ERK activation in
migrating PecamKO monolayers (data not shown). Inappropriate activation of FAK and
ERK in confluent PecamKO cells indicates dysfunctional signaling in the absence of an
appropriate migratory stimulus, and this signaling proves ineffective in coordinating
migration of PecamKO monolayers when that wounding stimulus is actually provided.
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Figure 16: Galphai2 signaling in PECAM-1 mediated migration.
A. PTX abrogates the wound-healing advantage of PecamRC endothelial cells
(* p < 0.005 vs control, n = 8).
B. EDG-1 receptor mediated signaling releases active GTP bound Galphai2, which
activates ERK, FAK and src. Pertussis toxin (PTX) directly inhibits Galphai2.
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Figure 17: Increased ERK and FAK signaling in PecamKO cells.
Confluent endothelial cells were evaluated for:
A. Activated ERK (PERK) and B. FAK phosphorylated at Y397 (PFAK). Quantitation of
PERK normalized to total ERK and PFAK normalized to total FAK revealed significantly
increased activation of both FAK and ERK in PecamKO (* p < 0.05 vs PecamRC; n = 4).
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PECAM-1 promotes coordinated migration to sphingosine-l-phosphate

PECAM-1-mediated wound healing is Rho-dependent and sensitive to PTX,
consistent with heterotrimeric G protein-mediated signaling such as that which occurs in
response to sphingosine-l-phosphate (SIP). Sphingosine-l-phosphate (SIP) is a major
serum-derived mediator of endothelial chemotaxis, wound-healing endothelial migration,
angiogenesis, and vascular maturation (English et a l, 2001). To assess SIP-mediated
migration, I measured wound healing in the absence of serum-derived sphingolipids, with
physiologic levels of SIP added back, and in baseline sphingolipid-replete endothelial
culture medium containing 10% FBS. Sphingolipid-free medium was prepared using
FBS that had been charcoal-stripped to deplete it of sphingolipids (CS-FBS). Such
treatment depletes SIP without significantly affecting levels of non-lipid growth factors
such as VEGF and FGF-2 (English et aL, 2000).
Wound healing migration in sphingolipid-depleted CS-FBS medium was
compared to migration in medium supplemented with 100 nM SIP [about half the
concentration of SIP in normal human plasma (Yatomi et al., 1997)] as well as to
migration in baseline sphingolipid-replete medium (Figure 18). PecamRC cells
responded to SIP supplementation and to sphingolipid-replete medium with significantly
increased migration, whereas PecamKO cells experienced no such increase in wound
healing migration, whether in the presence of sphingolipids in general or SIP
specifically. Two-way ANOVA revealed a statistically significant cell type by treatment
effect, the difference in the response of PecamKO versus PecamRC cells to SIP. In fact
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there was even a nonsignificant decrease in migration of PecamKO cells with SIP
supplementation and a significant decrease in wound healing in sphingolipid-replete
media. It is tempting to speculate that this decrease may be due to the high nondirected
motility seen in PecamKO endothelial cells; a further increase in random initiation of
motility in response to SIP may further interfere with the coordinated, directional nature
of wound healing migration. One would predict that while the single cell Transwell™
motility of PecamKO ceils may increase somewhat over an already high baseline in the
presence of SIP, their directed motility in response to an SIP gradient would be severely
compromised.
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Figure 18: Lack of appropriate SIP response in PecamKO cells.
Wound healing migration was assessed in sphingolipid-depleted media (CS-FBS), in
CS-FBS supplemented with 100 nM SIP, and in non-depleted media (FBS). PecamRC
cells had increased migration from in response to SIP or sphingolipid-replete media,
whereas PecamKO cells had no such increase. (* p < 0.005 vs CS-FBS, n = 8). Two-way
ANOVA reveals a significant cell type by treatment effect (F = 16.86, p < 0.000005)
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PECAM-1 localizes to caveolin-positive lipid rafts

Lipid rafts are cholesterol-rich liquid-ordered subdomains within the liquiddisordered plasma membrane (Galbiati et aL, 2001). Such lipid raft domains have been
found to help segregate associated proteins to the leading edge versus the rear of certain
polarized migrating cells (Gomez-Mouton et al., 2001). A subset of lipid rafts which
contain oligomerized caveolin-1 form small invaginations or caveolae which are
particularly enriched in vascular endothelium. A number of signaling proteins including
heterotrimeric G proteins, src and H-ras localize to these endothelial subdomains (BarSagi, 2001; Lisanti et al., 1994), providing spatially localized signaling information that
could potentially contribute to polarized cellular behaviors including migration.
Although caveolae as such are not concentrated at cell-cell junctions, caveolin-positive
low density lipid raft domains have also been found to interact with components of
adherens junctions (Galbiati et al., 2000), tight junctions (Nusrat et al., 2000),
glycophosphoinositol-linked adhesion molecules (Harris and Siu, 2002), and even gap
junctions (Schubert et al., 2002), and as such could play a role in the loosening of cell
cell adhesions that permits coordinated migration of cells into a wound to occur.
I used sucrose density gradient fractionation to isolate the low density caveolinpositive lipid raft fraction of PecamRC and PecamKO endothelial cell monolayers
(Figure 19a). Methyl B cyclodextrin (mBcd) disperses low density lipid rafts by
depleting them of cholesterol. Treatment with mBcd eliminated the low density caveolin
positive fraction, confirming that it consists of lipid rafts including caveolae.
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Interestingly, PECAM-1 was found to colocalize with caveolin-1 to the lipid raft fraction
(Figure 19b); mBcd treatment also disrupted the low density fractionation of PECAM-1.
To determine whether the raft localization of PECAM-1 might relate to its role in
promoting coordinated endothelial migration, I assessed the effect of raft disruption on
wound healing and single cell motility. It must be stressed that the cellular effects of
mBcd treatment are not limited to raft disruption, but that membrane cholesterol depletion
additionally has a wide range of nonspecific effects including plasma membrane
depolarization and a nonspecific depletion of Ca2+ stores (Pizzo et al., 2002). Thus these
experiments are best interpreted as a way to rule out (or not) rather than a way to rule in
(or not) the possibility o f a role of raft localization of PECAM-1 in migration.
Additional complications arise from the fact that raft disruption interferes with
multiple signaling pathways, not just those potentially associated with PECAM-1. In
particular, mBcd disrupts the raft localization of H-ras (Bar-Sagi, 2001) and hence its
ability to activate MEK and subsequently ERK. Treatment with 2 mM mBcd inhibits
ERK activation in wound healing PecamRC and PecamKO endothelial cells (Figure
20a). Treatment with 10 pm U0126, a MEK inhibitor, to inhibit ERK signaling
confirmed its necessary role in both wound healing and single cell motility (Figure 20b),
meaning that mBcd-induced inhibition of ERK signaling must be accounted for in the
interpretation of raft disruption experiments.
In order to differentiate the effect of raft disruption from that of the concomitant
inhibition of ERK signaling, endothelial cells were treated with 10 pm U0126 plus or
minus 2 mM mBcd to eliminate ERK signaling even in the absence of raft disruption.
Interestingly, mBcd treatment in the absence of ERK signaling decreased endothelial
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wound healing (Figure 21a) but increased single cell motility (Figure 21b). Thus the
effect of raft disruption on endothelial migration is analogous to the inhibition of Rho
signaling or the depletion of PECAM-1 expression of endothelial cells. (Similar results
were also obtained in the absence of U0126 to inhibit MEK). While any experiments
utilizing mBcd to disrupt rafts are necessarily nonspecific and may be attributable to nonraft-mediated effects of mBcd, these experiments at least fail to rule out the possibility
that rafts may play a role in promoting coordinated wound healing migration, and that the
raft localization of PECAM-1 may be pertinent to its role in mediating these effects.
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Figure 19: PECAM-1 localizes to a low density raft fraction.
A. Low density, caveolin positive lipid rafts separate from most other proteins by sucrose
gradient fractionation. Methyl p cyclodextrin (mpcd) disrupts lipid rafts and disperses
the low density caveolin positive fraction.
B. PECAM-1 cofractionates with lipid rafts in PecamRCcells, and disappears from the
low density fraction upon raft disruption.
56

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

A.
PecamRC
PERK

PecamKO

" * * * **

ERK
m|5cd

B.

m|3cd

Nondirected
motility

Wound
healing
300
u

4 -t

I—

CO

c£ t1'
cs

fl>

U0126
■PecamRC
■PecamKO

Figure 20: ERK signaling supports both motility and wound healing:
A. Raft disruption interrupts ERK signaling in wound healing endothelial cells.
B. Treatment with the MEK inhibitor U0126 at 10 pm to suppress ERK activation
interferes with both single cell and wound healing motility in PecamRC and PecamKO
cells, (n = 16 for wound healing, n = 9 for motility; *p < 0.005)
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Figure 21: Methyl B cyclodextrin inhibits wound healing and increases motility.
Cells were pretreated with U0126 to block ERK activation independent of raft disruption;
the effect of mBcd treatment and raft disruption on wound healing migration was evaluated.
A. Wound healing migration decreases significantly upon mBcd treatment.
(n = 8, *p < 0.05 vs U0126 alone)
B. Single cell motility increases upon m(kd treatment (n = 9, *p < 0.05 vs U0126 alone).
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PECAM-1 modulates the relative recruitment of Galphai2 and Galphal3 to rafts

PECAM-1 cofractionates with low density caveolin-positive lipid rafts, and raft
integrity promotes coordinated wound healing migration over nondirected single cell
motility. PECAM-1 expression is needed for an effective coordinated migration response
to SIP. Galpha subunits also localize to low density lipid rafts and move in and out of
caveolae (Oh and Schnitzer, 2001). Caveoiin-1 interactions may modulate heterotrimeric
G protein signaling: either directly by binding the inactive, GDP-bound version of
Galpha heterotrimeric protein subunits and inhibiting GDP/GTP exchange (Li et al.,
1995), or indirectly by transiently sequestering dissociated Galpha subunits, desensitizing
signaling via heterologous seven transmembrane receptors that share the same G protein
(Murthy and Makhlouf, 2000). Finally, overexpression experiments in several nonendothelial cell lines have demonstrated that EDG-1 localizes to caveolin-positive low
density lipid rafts (Igarashi and Michel, 2000), a process that is required for ligandinduced receptor internalization and resensitization (Kohno et al., 2002). Therefore the
relative recruitment of Galpha subunits to caveolin positive rafts, and their accessibility
to either EDG family receptors or to inhibitory associations with caveolin-1, may have a
direct bearing on Galpha subunit localization and degree of activation.
SIP-mediated migration has a pertussis-inhibitable, EDG-1/Galphai2 mediated
component which results in activation of ERK signaling and FAK phosphorylation, and
an EDG-3 mediated component that couples to Galphal3, contributing to Rho activation.
The ERK, FAK, and Rho signaling characteristics of PecamKO as compared to those of
PecamRC endothelial cells suggest a model in which the Galphai2-mediated signal is
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promiscuously activated, and the Galphal3 component is defective, in the absence of
PECAM-1. Given the potential role o f raft localization in modulating heterotrimeric G
protein mediated signaling, I assessed the relative targeting of Galphai2 versus Galphal3
to rafts in PecamRC versus PecamKO endothelial cells (Figure 22a). The results of
these preliminary experiments were consistent with a role for PECAM-1 in supporting
the targeting of Galpha subunits to lipid rafts: the ratio of Galphai2 to Galphal3 in the
low density caveolin positive fraction was decreased by more than naif in PecamKO as
compared to PecamRC endothelial cells (Figure 22b).
To begin to explore how the raft localization of PECAM-1 may contribute to
Galpha mediated Rho signaling, I assessed the tyrosine phosphorylation of pl20RasGAP
-associated pl90RhoGAP in PecamRC and PecamKO endothelial cells that had been
treated with mficd to disperse rafts (Figure 23a). PecamKO endothelial cells have
increased levels of pl90RhoGAP tyrosine phosphorylation and pl20RasGAP association
at baseline, which should in turn promote pl90RhoGAP activation, and therefore likely
contributes to the low baseline RhoGTP levels in the absence of PECAM-1 (Figure 10).
Raft dispersion (mficd treatment) increased pl20RasGAP-associated pl90RhoGAP
tyrosine phosphorylation in PecamRC endothelial cells to levels similar to those seen in
PecamKO cells (Figure 23b). Cholesterol depletion via mficd treatment is a fairly
nonspecific treatment, as discussed in the preceding section. Nevertheless, it should
prove fruitful to explore the potential role of PECAM-1 in promoting Galphai2-mediated
src activation and pl90RhoGAP tyrosine phosphorylation.
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Figure 22: PECAM-1 modulates raft recruitment of Galpha subunits.
A. Western blots demonstrate raft localization of Galphai2 and Galphal3 subunits.
B. Quantitation reveals higher ratio of Galphai2:Galphal3 in the presence of PECAM-1
(n = 4, *p < 0.05).
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Figure 23: Methyl Bcyclodextrin treatment increases pl90RhoGAP PY.
A. Western blot showing tyrosine phosphorylation of pl90RhoGAP coprecipitating
with pl20RasGAP.
B. Quantitation reveals significant increase in pl90RhoGAP PY in response to m|3cd
treatment in PecamRC cells, to levels comparable to PecamKO cells.
(n = 2, *p < 0.05 vs PecamRC)
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Discussion

The data presented above suggest a significant new role for PECAM-1 in
balancing coordinated wound healing migration and nondirected motility of endothelial
cells. The PECAM-1 knockout mouse is overtly developmentally normal, but
abnormalities of endothelial function become apparent in response to appropriate insult
During the chronic phase of foreign body inflammation, for example, angiogenesis is
severely compromised in the PECAM-1 knockout mouse (Solowiej et al., 2002). An in
vitro model of angiogenesis likewise reveals a prominent defect in tube formation in
immortalized lung endothelial cells derived from the PECAM-1 knockout mouse
(Solowiej et aL, 2002). Embryonic endocardial cells derived from the cardiac cushion of
the PECAM-1 knockout mouse, on the other hand, are aberrantly resistant to glucosemediated inhibition of VEGF-induced scattering motility (Enciso et al., 2003). PECAM1 deficient endothelial cells, then, are on the one hand defective in forming a stable new
vasculature, and conversely are resistant to inhibition of endocardial cell motility.
Consistent with their dichotomous migratory behavior in vivo, PecamKO
endothelial cells exhibit enhanced nondirected single cell motility and lamellipodial
extension formation at the expense of wound-healing migration. The contribution of
PECAM-1 to this migratory phenotype was confirmed by depleting PECAM-1 in primary
endothelial cells using antisense technology. The migratory differences are accounted for
by a selective deficiency of RhoGTP as opposed to RacGTP in PecamKO cells, since
inhibition of either Rho itself or the Rho effector pl60ROCK reproduced the PECAM-1deficient migratory phenotype.
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The decrease in RhoGTP loading could be at least partially attributed to increased
activation of pl90RhoGAP, a GTPase activating protein, as marked by tyrosine
phosphorylation and association of pl90RhoGAP with pl20RasGAP. Figure 24a
delineates growth factor and integrin engagement-mediated lamellipodial extension and
initiation of motility: some growth factors such as VEGF (Soga et al., 2001) activate Rac,
which itself inhibits Rho (Sander et al., 1999); other growth factors (Haskell et al., 2001)
and integrins (Arthur et al., 2000) activate src family kinases which phosphorylate and
activate pl90RhoGAP, inhibiting Rho indirectly. In fact, overexpression of
pl90RhoGAP alone derepresses Rac-mediated lamellipodial extension formation and
enhances motility (Arthur et al., 2000). The insensitivity of PECAM-1-deficient
endocardial cells to glucose-mediated suppression of VEGF-induced motility may thus be
attributable to baseline low RhoGTP. In fact, like primary PECAM-1-deficient
endocardial cells, PecamKO endothelial cells are resistant to glucose-mediated inhibition
of single cell motility; pretreatment with an inhibitor of the Rho effector pl60ROCK
abrogates the inhibitory effect of glucose on PecamRC endothelial cell motility.
SIP is a major endothelial chemotactic component of serum which engages EDG1 and EDG-3 seven-transmembrane receptors to mediate endothelial migration and
angiogenesis (Lee et al., 1999a; Lee et al., 1998) via downstream signaling through
Galphai2 to FAK, ERK, and src (Lee et al., 1999b; Rosenfeldt et al., 2001) and through
Galphal3 to Rho (Figure 24b) (Buhl et al., 1995; Offermanns et al., 1997). The woundhealing advantage of PecamRC cells is not only Rho-dependent but PTX-inhibitable, a
pattern characteristic of heterotrimeric G protein-mediated endothelial migration such as
that mediated by SIP. Physiologic levels of SIP increase wound healing migration of
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PecamRC endothelial cells, as expected; PecamKO endothelial cells in contrast are not
responsive to SIP. Indeed the relative wound-healing advantage of PecamRC cells is
much decreased in sphingolipid-depleted serum, implicating the heterotrimeric G proteinmediated sphingolipid signaling pathway in the promotion of wound healing migration
by PECAM-1. Elevated threonine/tyrosine phosphorylation of ERK and tyrosine
phosphorylation of FAK in confluent PecamKO cells is consistent with dysregulated and
ineffective Gaiphai2 signaling downstream of EDG-1 receptor. Src activity is also likely
increased in PecamKO cells: increased FAK at PY397 indicates that more src is likely
bound and activated at focal contacts (Eide et al., 1995); and tyrosine phosphorylation of
pl90RhoGAP, which is also increased, is likewise mediated by src (Arthur et al., 2000).
Global activation of these pathways in and of itself is insufficient to permit
directed migration and coordinated wound-healing. EDG-1 null fibroblasts, like
PecamKO endothelial cells, display aberrant FAK and src activation but a decreased
wound healing response to SIP; local FAK and src activation at the leading edge
promotes the directed extension formation and migration of wildtype fibroblasts in
response to SIP (Rosenfeldt et al., 2001). Interestingly, another immunoglobulin family
molecule containing ITIM sequences in its cytoplasmic domains, SHPS-1, may play a
similar role to that of PECAM-1 in fibroblasts: expression of SHPS-1 lacking its
cytoplasmic domain in fibroblasts blocks RhoGTP activation and wound healing
migration, promotes extension formation, and increases ERK and FAK phosphorylation
(Inagaki et al., 2000).
A model of defective sphingosine-1-phosphate-mediated signaling and Rho
activation in PECAM-1-deficient endothelial cells incorporates these observations
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(Figure 24b,c). In PECAM-1-positive endothelial cells SIP signals through Galphai2
and Galphal3 in a coordinated maimer to produce directed extension formation and
directed wound healing migration rather than nondirected motility (Figure 24b). In
PECAM-1-deficient endothelial cells EDG-1 and Galphai2 are activated in a non
coordinated manner, leading to baseline activation of ERK, FAK, and src (Figure 24c).
Phosphorylation activates pl90RhoGAP and suppresses RhoGTP; EDG-3-mediated
signaling to Gaiphal3 is insufficient to activate Rho, favoring extension formation and
nondirected motility over directed wound healing migration. This lack of coordinated
responsiveness to serum sphingolipid chemotactic signals may account for the poor
angiogenesis into polyvinyl acetate sponge implants in the PECAM-1 knockout mouse in
a model of the chronic phase of foreign body inflammation (Solowiej et al., 2002).
PECAM-1 modulates the selective recruitment of Galphai2 versus Galphal3 to caveolin
positive low density lipid raft fractions, where their activity might be modulated via
association with EDG receptors and with caveolin-1. It will be rewarding to investigate
the circumstances under which PECAM-1-mediated modulation of heterotrimeric Gprotein signaling to Rho family small G proteins becomes pathophysiologically relevant.
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Figure 24: Model for role of PECAM-1 in endothelial motility.
A. Growth factor or integrin signaling coordinately activates Rac and inhibits Rho via src
mediated phosphorylation of pl90RhoGAP, allowing lamellipodial extension and motility.
B. In PECAM-positive cells SIP signals in a coordinated manner to produce directed
extension formation and wound healing rather than nondirected motility.
C. In PECAM-null endothelium noncoordinated EDG receptor signaling favors extension
formation and nondirected motility over directed wound healing.
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Chapter 3: The PECAM-1 ITIM in endothelial wound healing migration

Summary

Platelet-Endothelial Cell Adhesion Molecule-1, PECAM-1, a transmembrane
endothelial adhesion protein, binds and activates the tyrosine phosphatase SHP-2 via
pnospnotyrosines 663 and 686. PECAM-1 phosphorylation and recruitment of SHP-2 is
regulated by cell-cell and cell-substrate adhesion. PECAM-1 is dephosphorylated on
tyrosine 686 during endothelial migration, resulting in diffuse dispersal of PECAM-1 and
SHP-2. Overexpression of native PECAM-1 slowed, and nonphosphorylatable PECAM1 increased, endothelial migration, implying that the SHP-2-regulatory phosphotyrosines
negatively regulate migration. Using differentially phosphorylated recombinant proteins
I found that phosphotyrosine 686 preferentially mediates binding and 663 mediates
activation of SHP-2 by PECAM-1. In PECAM-1-null endothelial cells, SHP-2 bound
and dephosphorylated an alternative set of phosphoproteins and its distribution to a
Triton-insoluble, likely cytoskeletal fraction was significantly decreased. Tyrosine
phosphorylation of beta catenin and focal adhesion kinase was increased in endothelial
cells overexpressing nonphosphorylateable PECAM-1. Thus homophilically engaged,
tyrosine-phosphorylated PECAM-1 locally activates SHP-2 at cell-cell junctions; with
disruption of the endothelial monolayer, selective dephosphorylation of PECAM-1 leads
to redistribution of SHP-2 and pro-migratory changes in phosphorylation of cytoskeletal
and focal contact components.
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Introduction

Platelet-Endothelial Cell Adhesion Molecule, or PECAM-1, is a homophilically
adhesive transmembrane glycoprotein (Albelda et al., 1990; Newman et al., 1990) which
modulates endothelial migration, tube formation, and angiogenesis in vivo and in vitro
(Cao et al., 2002; DeLisser et al., 1997; Kim et al., 1998). Many of these functions
localize to the Immunoreceptor Tyrosine-based Inhibitory Motif or ITIM (Newman,
1999), which binds and activates SH2-domain-containing proteins (Pumphrey et al.,
1999). A model of the PECAM-1 ITIM seen in Figure 25a shows the orientation of
ITIM tyrosines 663 and 686 within a bend in the cytoplasmic domain (Kim et al., 1998).
ITIM tyrosine 686 is dephosphorylated in endothelial cells upon engagement of 1
integrins (Lu et al., 1996) and during normal yolk sac vasculogenesis (Pinter et al., 1997);
dephosphorylation is abrogated during abnormal vasculogenesis in glucose-induced
embryopathy (Pinter et al., 1999). Conversely, PECAM-1 mutated at tyrosine 686
increases endothelial wound healing migration (Kim et al., 1998). PECAM-1
phosphorylation at tyrosine 686 also increases homophilic cell-cell adhesion, supporting
a role for the ITIM in inside-out signaling (Famiglietti et al., 1997; Yan et al., 1995)
In endothelial cells the tyrosine phosphatase SHP-2 is a major PECAM-1 ITIM
partner (Jackson et al., 1997; Masuda et al., 1997). SHP-2 was identified as a homologue
of a Drosophila gene, csw, involved in early development downstream of a receptor
tyrosine kinase (Freeman et al., 1992). It is a ubiquitously-expressed protein tyrosine
phosphatase which is activated by occupancy of its two tandem SH2 domains (Dechert et
al., 1994; Sugimoto et al., 1993). The crystal structure of SHP-2 (Figure 26a) has
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revealed that a portion of the N-terminal SH2 domain (N-SH2) sterically blocks access to
the active site (Barford and Neel, 1998). Phosphotyrosine engagement of the N-SH2
domain shifts it out of the active site, sterically activating the en2 yme (Hof et al., 1998).
Engagement of the C-terminal SH2 domain contributes to binding specificity of
appropriately spaced phosphotyrosines, but does not contribute to enzyme activation.
The spacing of the SH2 domains of SHP-2 (Eck et al., 1996) confers on it high specificity
for engagement by the tandem phosphotyrosines located in ITIMs (Ottinger et al., 1998),
including that o f PECAM-1 (Jackson et al., 1997), as opposed to the more closely spaced
bisphosphorylated ITAMs (immunoreceptor tyrosine-based activation motifs) (Ottinger
et al., 1998). Thus the phosphorylation of one or both PECAM-1 ITIM tyrosines may be
expected to have differential effects both on SHP-2 recruitment and on modulation of its
tyrosine phosphatase activity.
Coordinated migration of endothelial cell monolayers involves loosening of
adherens junctions and focal contact turnover. Vascular endothelial cadherin (VEcadherin) plays a large role in maintaining tight endothelial cell-cell interactions at
adherens junctions (Corada et al., 1999). These junctions undergo major reorganization
at the migrating front of a wounded endothelial monolayer (Lampugnani et al., 1995).
Beta catenin becomes tyrosine phosphorylated in response to stimuli that induce an
increase in vascular permeability and angiogenesis, such as vascular endothelial growth
factor or VEGF (Cohen et al., 1999). Linkage of VE-cadherin to the actin cytoskeleton
via beta catenin association with alpha catenin (Provost and Rimm, 1999), and hence the
stability of cadherin-mediated cell-cell adhesion, is regulated by beta catenin tyrosine
phosphorylation (Ukropec et al., 2002).
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A number of protein tyrosine phosphatases, including LMW-PTPase (Taddei et
al., 2002), RPTPase (receptor-type protein tyrosine phosphatase) beta/zeta (Meng et al.,
2000), PTP1B (Balsamo et al., 1998), and PTP-LAR (leukocyte common antigen related)
have been implicated in the maintenance of cadherin-mediated cell-cell adhesion through
dephosphorylation of beta catenin by overexpression in non-endothelial cells. In
endothelial cells, and in the absence of overexpression, SHP-2 is the only protein tyrosine
phosphatase that has been implicated in beta catenin dephosphorylation. Endothelial
PECAM-1 binds tyrosyl-phosphorylated beta catenin (Ilan et al., 1999); beta catenin is
therefore in a position to be targeted for dephosphorylation by PECAM-1 ITIM activated
SHP-2. Although no direct evidence of SHP-2-mediated dephosphorylation of beta
catenin is available, the loss of SHP-2 from adherens junction complexes in response to
thrombin (Ukropec et al., 2000) or shear stress (Ukropec et al., 2002) correlates with
increased beta catenin phosphorylation and loss of cadherin-cytoskeletal linkage.
Focal adhesion kinase (FAK) activity, mediated by autophosphorylation (Owen et
al., 1999), is also required for migration (Gilmore and Romer, 1996). SHP-2 modulates
tyrosine phosphorylation of FAK and thus focal contact turnover and cell motility
(Gilmore and Romer, 1996; Yu et al., 1998), and FAK tyrsoine phosphorylation is
increased in PECAM-1 deficient endothelial cells (Figure 17b), providing another
potential target for PECAM-1 ITIM-associated SHP-2 dephosphorylation. The
functional role of PECAM-1-mediated modulation of SHP-2 tyrosine phosphatase
activity in endothelial cell migration however remains unclear. To this end I studied the
role of the PECAM-1 ITIM in migration-related SHP-2 recruitment and activation, and
the dephosphorylation of potential target phosphoproteins relevant to migration.
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Figure 25: A model of the PECAM-1 ITIM.
A. A model of the PECAM ITIM reveals a loop in the cytoplasmic domain which makes
tyrosines 663 and 686 readily available for phosphorylation
(Kim C.S. et al, Lab Invest. 78:583,1998).
B. The PECAM-1 cytoplasmic domain was as a GST fusion protein; the ITIM tyrosines
were individually mutated to allow for selective phosphorylation.
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Figure 26: Recombinant SHP-2 production.
A. Model derived from crystal structure of SHP-2 (Hof P. et al, Cell 92:441 (1998).
N-SH2 domain moves out of catalytic cleft upon PY engagement (C = catalytic cysteine)
B. GST-SHP-2 was captured on glutathione beads, then thrombin-cleaved to remove GST.
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Results

SHP-2 is preferentially bound by PECAM-1 phosphotyrosine 686

The PECAM-1 cytoplasmic domain was expressed as a fusion protein, with
glutathione-S-transferase at its N-terminal (Lu et al., 1997) allowing ease of purification
using glutathione agarose beads. GST-PECAM-i containing site-directed mutations at
tyrosines 663 and 686 of the ITIM was produced in bacteria expressing a kinase capable
of phosphorylating available tyrosines (Figure 25b). Western blotting with
phosphospecific antibodies (Figure 27a) (Lu et al., 1996) confirmed site-specific tyrosine
phosphorylation. Recombinant SHP-2 (rSHP-2) was cleaved from its GST tag at an Nterminal thrombin cleavage site (Figure 26b). Pulldown assays using GST-PECAM-1
assessed the contribution of the respective ITIM phosphotyrosines to SHP-2 recruitment
(Figure 27b). PECAM-1 phosphorylated only at tyrosine 686 pulled down the same
amount of SHP-2 as dually phosphorylated PECAM-1; lack of phosphorylation at 686
however significantly decreased SHP-2 binding. Thus both ITIM tyrosines are capable
of binding SHP-2, but loss of phosphorylation at tyrosine 686 would likely lead to a
significant decrease in PECAM-1-associated SHP-2.
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Figure 27: Contribution of HIM tyrosines to SHP-2 binding.
A. GST-PECAM-1 phosphorylation was confirmed with phosphospecific antibodies.
B. Pulldown assay using phosphorylated GST-PECAM-1 as bait 663F-PY pulls down as much
SHP-2 as PEC-PY, but 686F-PY pulls down significantly less, (n = 5, *p < 0.005 vs PEC-PY).
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PECAM-1 phosphotyrosine 663 preferentially activates SHP-2

Engagement of the SH2 domains of SHP-2 serves not only to recruit the
phosphatase but to activate it (Barford and Neel, 1998; Dechert et al., 1994). All reports
of PECAM-l-mediated SHP-2 activation thus far have used phosphorylated peptides
(Pluskey et al., 1995). However, the secondary and tertiary structure of the PECAM-1
cytoplasmic domain may have profound effects on SHP-2 binding and activation. I
measured SHP-2 activity by monitoring dephosphorylation of the synthetic substrate
pNPP (p nitrophenyl phosphate). Recombinant SHP-2 (rSHP-2) had a baseline activity
of 15 nM pNP /minute, while rSHP-2 mutated in its catalytic acid (Flint et al., 1997) was
inactive as expected (Figure 28a). The responsiveness of rSHP-2 to engagement of its
SH2 domains was tested using ITIM phosphopeptides. Phosphopeptide 663 produced a
dose-dependent increase in SHP-2 activity, while the same peptide in nonphosphorylated
form produced no increase in phosphatase activity over baseline (Figure 28b).
The relative role of the two ITIM phosphotyrosines was then tested using
phosphopeptides: while phosphopeptide 663 activated rSHP-2 in a dose-dependent
manner, neither nonphosphorylated 663 nor phosphopeptide 686 did so (Figure 29a).
Activation was then tested in the context of the full PECAM-1 cytoplasmic domain
(Figure 29b). PECAM-1 phosphorylated at 663 alone activated SHP-2 as well as dually
phosphorylated PECAM-1, whereas PECAM-1 phosphorylated at 686 caused very little
activation over baseline. Thus the two individual phosphotyrosines of the PECAM-1
ITIM play individual and complementary roles in modulation of SHP-2 activity, with
phosphotyrosine (PY) 686 recruiting and PY 663 activating the phosphatase.
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Figure 28: Assessment of recombinant SHP-2 phosphatase activity.
Phosphatase activity was measured using p-nitrophenyl phosphate (pNPP) as substrate.
A. rSHP-2 dephosphorylates pNP at 15 nM/min at baseline; a loss of function mutant
(D425A) is inactive (n = 5, *p < 0.005).
B. Stimulation of SHP-2 activity by phosphorylated (663-PY) vs nonphosphorylated
(663-Y) ITIM phosphopeptide.
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Figure 29: SHP-2 is preferentially activated by PY 663.
A. Phosphopeptides 663-PY but not 663-Y or 686-PY stimulate rSHP-2 activity in a dose
dependent manner.
B. Stimulation of rSHP2 activity by rPECAM-1. PECAM-1 phosphorylated at both ITIM
tyrosines (PEC-PY) or at 663 alone (686F-PY) but not 686 alone (663F-PY) significantly
activated SHP-2 (n = 6, *p < 0.005).
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The PECAM-1 ITIM is selectively dephosphorylated during migration

PECAM-1 localizes to cell-cell contacts in confluent endothelial cells (Albelda et
al., 1990); homophilically-engaged PECAM-1 is tyrosine-phosphorylated and able to
bind SHP-2 (Bird et al., 1999). Accordingly PECAM-1 and SHP-2 co-localized to cell
cell borders of confluent human umbilical vein endothelial cells, whereas migrating cells
displayed diffuse PECAM-1 and SHP-2 staining (Figure 30). Previous work from our
laboratory has evaluated the relative phosphorylation of each of the PECAM-1 ITIM
phosphotyrosines during migration (Gratzinger et al., 2003a). To assess PECAM-1 PY
during migration, confluent bovine aortic endothelial cells (BAECs) were wounded by
mechanical scraping. The remaining concentric circles of migrating endothelium were
evaluated at 24 hours post wounding; by 72 hours, they had reachieved confluence.
Immunoprecipitation revealed decreased total PECAM-1 PY, and consequently SHP-2
association, in migrating BAECs 24 hours post-wounding; at 72 hours, the newly
confluent BAECs reachieved baseline PECAM-1 PY (Figure 31a). Analysis with
phosphospecific antibodies revealed that relative dephosphorylation at tyrosine 686
(74%) was much greater than that at tyrosine 663 (21%) (Figure 31b). Thus,
dephosphorylation of the PECAM-1 ITIM during migration occurs preferentially at the
site that recombinant protein pulldown experiments implicate in recruiting SHP-2.
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confluent

migrating

Figure 30: Colocalization of SHP-2 and PECAM-1.
Immunofluorescence reveals cell-cell border localization of both PECAM-1 (upper) and
SHP-2 (middle) in confluent human umbilical vein endothelial cells; colocalization is
shown at bottom. In migrating cells, PECAM-1 and SHP-2 are both diffusely localized.
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Figure 31: Preferential dephosphorylation at Y686 during migration.
A. Immimoprecipitation of PECAM-1 reveals decreased PY and SHP-2 association in
migrating BAECs. Quantitation reveals a > 50% decrease in PECAM-1 PY at 24 hours
wound healing, with baseline PY restored at confluence (72 hr) (n = 3, *p < 0.05 vs 0 hr).
B. Blotting with phosphospecific antibodies to the PECAM-1 ITIM reveals greater
dephosphorylation at Y686 than at 663 (n = 2, *p < 0.05 vs total PY).
(Work of M. Barreuther (D. Gratzinger, M. Barreuther, J.A. Madri,unpublished data).
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PECAM-1 expression localizes SHP-2 to a Triton-insoluble fraction

Immortalized lung endothelial cells derived from the PECAM-1 knockout mouse
(PecamKO) and reconstituted with full-length PECAM-1 (PecamRC) form contactinhibited confluent monolayers and maintain expression of endothelial markers such as
VE-cadherin (Graesser et al., 2002; Wong et al., 2000). To evaluate the role of PECAM1 in localizing SHP-2 to potential target pnosphoproteins, i assessed the relative
recruitment of SHP-2 to a Triton X-l 00 insoluble fraction. Less than half as much SHP-2
was found in the Triton-insoluble pellet in PecamKO as PecamRC endothelial cells;
Focal Adhesion Kinase (FAK) was by comparison found in comparable amounts
regardless of endothelial PECAM-1 expression status (Figure 32a). The Triton-insoluble
pellet represents cytoskeleton-associated proteins, but lipid raft components are also
Triton-insoluble. Sucrose density gradient fractionation of the low-density, caveolinpositive lipid raft fraction (Sowa et al., 2001) however failed to demonstrate any
significant partitioning of SHP-2 to rafts in either PecamKO or PecamRC endothelial
cells (Figure 32b); SHP-2 instead localized to the higher density fractions along with
beta actin.
The fact that PECAM-1 dependent SHP-2 partitioning to a Triton-insoluble
fraction appears cytoskeletal rather than raft-associated despite the large fraction of
PECAM-1 that fractionates in a low-density caveolin positive fraction (Figure 19)
requires further clarification. Several possibilities exist: one, that PECAM-1-associated
SHP-2 becomes dissociated at some point during the raft preparation process; two, that
SHP-2 largely associates with that fraction of PECAM-1 that is not localized to lipid
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rafts; three, that SHP-2 is simultaneously raft and cytoskeletally associated, but
fractionates with the cytoskeleton thanks to the properties of the separation technique;
and four, that the change in SHP-2 localization is due not only to direct co-localization of
SHP-2 with tyrosyl-phosphorylated PECAM-1, but to consequent changes in tyrosine
phosphorylation of other SHP-2 target proteins which likewise provide sites for SHP-2
binding contribute to the relocalization of SHP-2. A combination of alternate
biochemical methods of raft separation and immunostaining of intact cells should help to
clarify these issues.
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Figure 32: PECAM-1 modulates subcellular distribution of SHP-2.
Levels of SHP-2 and FAK in the Triton-insoluble pellet were normalized to actin.
A. PecamKO cells have significantly lower levels of SHP-2 but not FAK in the
Triton X-100 insoluble fraction (n = 6, *p < 0.05 vs PecamRC).
B. Sucrose density gradient fractionation separates caveolin-postive lipid rafts
(fractions 3-4) from nonraft proteins in p actin-positive fractions 9-11; SHP-2 is
not present in rafts in PecamRC or PecamKO endothelial cells.
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SHP-2 binds alternate target proteins in the absence of PEC AM-1

In the absence of PECAM-1, SHP-2 is inefficiently localized to a Triton-insoluble
fraction (likely cytoskeletal), and consequently likely has access to an alternate set of
target phosphoproteins. To test this hypothesis I immunoprecipitated SHP-2 from
PecamKO and PecamRC endothelial cells and evaluated for co-precipitating tyrosyl
phosphorylated proteins. SHP-2 from PecamRC and PecamKO endothelial cells
consistently co-precipitated different phosphoproteins. The major bands were of
apparent molecular weight ~125kD and 140kD, respectively, in PecamRC and PecamKO
cells. An additional band was appreciated at ~ lOOkD and 1lOkD, respectively.
Candidate blotting experiments for a number of signaling, adhesion and adaptor proteins
of these approximate sizes failed to identify the coprecipitating phosphoproteins; in
particular, neither beta catenin nor VE-cadherin were present in any discernible
quantitity. Further analysis will likely require direct analysis of the bands through in-gel
tryptic digests and peptide mass identification.
To determine whether these phosphoproteins are potential targets of SHP-2
phosphatase activity, SHP-2 was immunoprecipitated in the presence of orthovanadate to
inhibit tyrosine phosphatase activity. Orthovanadate was then washed out and SHP-2
allowed to dephosphorylate any co-precipitating phosphoproteins (Figure 33b). SHP-2
co-precipitated with different major phosphoproteins from PecamKO and PecamRC cells,
and these phosphoproteins were substrates for the tyrosine phosphatase activity of SHP-2.
Thus PECAM-1 is instrumental in localizing SHP-2 to a Triton-insoluble fraction in
endothelial cells, and in directing SHP-2 to specific target phosphoproteins.
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Figure 33: PECAM-1 modulates phosphoprotein association of SHP-2.
A. SHP-2 coprecipitates major phosphoproteins of apparent MW ~ 125kD and 140kD in
PecamRC and PecamKO endothelial cells, respectively.
B. Immunocomplex phosphatase assay: SHP-2 was IPed, dephosphorylation was allowed
to proceed for 0 or 20 min and coprecipitates were immunoblotted for PY. (*SHP-2)
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PECAM-1 ITEM signaling slows endothelial migration

To assess the role of PECAM-1 ITIM tyrosine phosphorylation in endothelial
wound healing migration, PecamRC endothelial cells were transiently transfected with
either wildtype PECAM-1 (PEC) or with PECAM-1 mutated in its ITIM domain (PEC
2F). Interestingly, PEC transfection slowed and PEC 2F transfection increased wound
healing migration (Figure 34a). Thus the functional PECAM-1 ITIM domain, and its
associated SHP-2, acts in a dose-dependent manner to retard migration. The ITIMdeficient PECAM-1 construct appears to act as a dominant negative, increasing wound
healing migration in PECAM-expressing endothelial cells. It is not the case that a global
increase in SHP-2 activity due to PECAM-ITIM-mediated activation retards migration.
In fact, overexpression of wildtype SHP-2 increases wound healing migration, whereas a
loss of function SHP-2 mutant (C459S) slows migration (Figure 34b). SHP-2 mutated
in its C-terminal SH2 domain to prevent phosphotyrosine engagement, [R138K, (Pluskey
et al., 1995)], proved to be equally effective in increasing endothelial migration as was
wildtype SHP-2. Thus the positive role of SHP-2 in increasing endothelial wound
healing is unlikely to be regulated by ITIM-bearing proteins such as PECAM-1. The role
of PECAM-1 ITIM-associated SHP-2 activity in wound healing migration on the other
hand appears to be that o f a negative modulator.

87

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ITIM signaling modulates beta catenin and FAK phosphorylation

Decreased ITIM phosphorylation and thus lower PECAM-1-mediated SHP-2
tyrosine phosphatase activation should lead to decreased dephosphoiylation of SHP-2
targets. Adherens junction component beta catenin dissociates from the actin
cytoskeleton when tyrosine phosphorylated, as in response to shear stress (Ukropec et al.,
2002). Immunoprecipitation revealed significantly increased beta catenin tyrosine
phosphorylation in PEC 2F transfected endothelial cells (Figure 35a). Focal adhesion
kinase (FAK) is a target of SHP-2 (Yu et al., 1998); FAK kinase activity in turn is
required for endothelial cell migration (Gilmore and Romer, 1996). Western blotting
with phosphospecific antibodies for the src-activating autophosphorylated tyrosine 397 of
FAK (Eide et al., 1995) revealed increased FAK PY 397 in PEC 2F transfected
endothelial cells (Figure 35b), pointing to a potential role for PECAM-1 in modulating
focal contact turnover.
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Figure 34: Role of Pecam ITIM domain in wound healing migration.
A. PecamRC cells were transiently transfected with wildtype (PEC) or ITIM defective
(PEC 2F) PECAM-1. (n = 8, *p < 0.01).
B. PecamRC cells were transiently transfected with wildtype (SHP2), loss of function
(C/S), or C-SH2 domain binding defective (R138K) SHP-2. (n = 4, p < 0.05)
89

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

beta catenin IP

control

PEC

PEC2F

PY
beta catenin

FAK western blot

control
PY 397

PEC

PEC2F

** - f l f

FAK <m* *m

Figure 35: Targets for ITIM-mediated dephosphorylation.
A. Immunoprecipitation of beta catenin reveals significantly increased PY with PEC 2F
transfection (n = 4, *p < 0.05).
B. Western blotting reveals increased FAK PY 397 in PEC2F-transfected cells
(n = 3, *p < 0.005).
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Discussion

The role of PECAM-1 in coordinated endothelial cell behaviors appears
paradoxical. As a whole, PECAM-1 plays a positive role in migration and angiogenesis
(Cao et al., 2002; DeLisser et al., 1997). Yet expression of ITIM-defective PECAM-1
increases migration in bovine aortic endothelial cells (Kim et al., 1998), implying a
negative reguiatory role for PECAM-1 signaling in coordinated motility. Restoration of
wound healing migration to PecamKO endothelial cells by PECAM-1 is independent of
signaling via the ITIM domain (Gratzinger et al., 2003b). In PecamRC endothelial cells,
on the other hand, expression of ITIM-functional PECAM-1 slows and ITIM-defective
PECAM-1 speeds wound healing migration. Thus PECAM-1 is required at baseline to
support migration, while ITIM-mediated signaling provides a damp or brake to modulate
that migration.
In migrating endothelial cells, loss of cell-cell contacts releases PECAM-1 from
the homophilic engagement that supports tyrosine phosphorylation and recruitment of
SHP-2 (Bird et al., 1999). Accordingly, we observed a diffuse relocalization of both
PECAM-1 and SHP-2 and a decrease in overall tyrosine phosphorylation and SHP-2
association with immunoprecipitated PECAM-1 in migrating endothelial cells. Using
phosphospecific antibodies we determined that dephosphorylation was overwhelmingly
at the second ITIM tyrosine, Y686, rather than Y663.
I assessed the effect of this dephosphorylation event on SHP-2 binding and
activation in vitro using recombinant SHP-2 and PECAM-1 cytoplasmic domain. Lack
of phosphorylation at tyrosine 686 significantly decreased SHP-2 binding, whereas
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phosphotyrosine 663 was dispensable for recruitment. In contrast, phosphotyrosine 686
did not contribute to SHP-2 activation, whereas PECAM-1 phosphoiylated at tyrosine
663 activated SHP-2 as well as did fully phosphoiylated PECAM-1. Engagement of the
N-SH2 domain of SHP-2 allosterically disinhibits the phosphatase active site (Baiford
and Neel, 1998). Interestingly, Biacore experiments using PECAM-1 ITIM
phosphopeptides have indicated that it is phosphotyrosine 663 that engages the N-SH2
domain (Jackson et ai., 1997), consistent with a model of activation of PECAM-1-bound
SHP-2 by phosphotyrosine 663.
Given the interaction of SHP-2 with phosphorylated PECAM-1 at cell-cell
borders, it is plausible that SHP-2 itself may be responsible for the dephosphorylation of
adjacent PECAM-1 molecules. The rem aining ITIM phosphotyrosine 663 could help to
backpropagate the dephosphorylation signal at the wound edge by sustaining SHP-2
activity toward adjacent phosphotyrosine 686. Since phosphorylation at tyrosine 686 is
required to sustain PECAM-1 mediated homophilic cell-cell adhesion (Famiglietti et al.,
1997), dephosphorylation at tyrosine 686 in one endothelial cell could be communicated
to adjoining cells via decreased PECAM-1 engagement (inside out signaling) and
consequent loss o f phosphorylation at tyrosine 686 in the neighboring cell (outside in
signaling).
In addition to any potential effects of SHP-2 on PECAM-1 phosphorylation and
homophilic adhesion, engaged, tyrosyl-phosphorylated PECAM-1 should direct SHP-2 to
target phosphoproteins involved in maintaining a stable, confluent as opposed to a loose,
migrating endothelial monolayer. Using detergent-insolubility and sucrose-gradient
fractionation techniques I determined that SHP-2 is inefficiently targeted to a Triton-
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insoluble, likely cytoskeletal fraction in PECAM-1 deficient endothelial cells.
Furthermore, SHP-2 associates with and is capable of dephosphorylating an alternate set
of phosphoproteins in the absence of PECAM-1.
I then transiently transfected endothelial cells with ITIM-defective PECAM-1
(PEC 2F) to interfere with their dephosphorylation. Beta catenin links adherens junction
component VE-cadherin to the actin cytoskeleton via alpha catenin; tyrosine
phosphorylation of beta catenin releases this linkage at the level of the beta catenin/alpha
catenin interaction (Ukropec et al., 2002). PECAM-1 binds tyrosyl-phosphorylated beta
catenin (Han et al., 1999); ITIM-regulated SHP-2 activity could thus modulate
phosphorylation of membrane-associated beta catenin. I found that PEC 2F transfection
increases overall beta catenin tyrosine phosphorylation without affecting VE cadherin
association, potentially loosening adherens junction-actin cytoskeletal interactions and
favoring migration.
Focal adhesion kinase (FAK) activity contributes to endothelial cell migration
(Gilmore and Romer, 1996) and FAK is a target for SHP-2 phosphatase activity (Yu et
al., 1998). SHP-2 but not FAK partitioning to the actin cytoskeletal fraction is decreased
in the absence of PECAM-1; thus PECAM-1 might modulate SHP-2- mediated
dephosphorylation of FAK. Indeed PEC 2F transfection increased phosphorylation of
FAK at src-activating tyrosine 397 (Eide et al., 1995); thus phosphorylated PECAM-1 in
confluent endothelial cells may serve to downregulate FAK activity in the absence of a
migratory stimulus.
Figure 36 presents a model of PECAM-1 mediated SHP-2 activation at
confluence and during endothelial migration. In confluent endothelial cells (Figure 36a),
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PECAM-1 is homophilically engaged at cell-cell borders and consequently is tyrosine
phosphorylated on its ITIM. SHP-2 is engaged via both tyrosines 686 and 663, which
respectively bind and activate the tyrosine phosphatase. SHP-2 targets proteins at the
cell-cell junction and within the Triton-insoluble fraction, including beta catenin and
FAK. Decreased tyrosine phosphorylation of beta catenin at adherens junctions would
favor alpha catenin association and coupling to the actin cytoskeleton. Decreased FAK
phosphorylation at tyrosine 397 would lower FAK activity and association of src kinase
activity, decreasing focal contact turnover necessary for migration.
In wounded, migrating endothelial monolayers (Figure 36b), PECAM-1 is not
homophilically engaged and becomes dephosphorylated, particularly at tyrosine 686.
SHP-2 becomes dissociated from PECAM-1, and beta catenin and FAK are no longer
targeted for dephosphorylation. Increased beta catenin tyrosine phosphorylation
promotes weakening of adherens junctions and their dissociation from the cytoskeleton.
Increased FAK activity promotes formation of focal complexes at the leading edge of the
migrating endothelial cell. Selective dephosphorylation of the PECAM-1 ITIM domain
appears to play a key regulatory role in coordinated endothelial migration.
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Figure 36: Role of PECAM-1 ITIM in endothelial migration.
Modulation of adherens junction and focal adhesion dynamics via PECAM-1 ITIM
mediated targetting and activation of SHP-2. See text for discussion.
(6 cat = beta catenin, VE cadh = VE cadherin, Y = tyrosine, P = phosphate)
95

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Chapter 4: Answers and Questions

Answers

PECAM-1 plays at least two distinct roles in modulating endothelial cell
migration: in one role, PECAM-1 helps to coordinate Galpha-protein mediated signaling
to promote Rho-mediated wound healing migration. In the other, the phosphorylated
PECAM-1 ITIM domain retards wound healing by modulating SHP-2 localization and
activation. Endothelial expression of PECAM-1 modulates localization of specific
Galpha protein subunits to caveolin-positive lipid raft subdomains, and hence the
localized activation state of downstream signaling pathways. Local suppression of
RhoGTP signaling (Arthur and Burridge, 2001) and activation of FAK, src and ERK
kinase activity (Pintucci et al., 2002; Rosenfeldt et al., 2001) promotes directed extension
formation as a component of a coordinated endothelial migratory response to mechanical
wounding. Global suppression of Rho signaling and activation of Galphai2-mediated
signaling pathways, on the other hand, promotes exuberant formation of lamellipodial
extensions and nondirected single cell motility at the expense of coordinated migration.
In addition to and distinct from the overall positive role of PECAM-1 in
coordinating endothelial wound healing, PECAM-1 ITIM-mediated signaling negatively
modulates the wound healing response. Failure of developmental stage specific
dephosphorylation of PECAM-1 ITIM tyrosine 686 in glucose-treated yolk sac
vasculature, for example, (Pinter et al., 1999) would be expected to interfere with
coordinated endothelial migration. It may thus partly explain the consequent faulty
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vasculogenesis that results in ectatic vessels, with failure to progress from the primary
capillary plexus stage to a serially branching mature vasculature. The PECAM-1 ITIM is
maximally phosphorylated in confluent as opposed to migrating endothelial cells (Lu et
al., 1996). In this situation SHP-2 is activated at cell-cell junctions in a cytoskeletally
associated fraction, maintaining low baseline levels of tyrosine phosphorylation of
adherens junction and focal adhesion components. Stimuli such as mechanical wounding
(M. Barreuther, unpublished data) and integrin engagement (Lu et al., 1996) promote
dephosphorylation of the PECAM-1 ITIM, particularly at the second ITIM tyrosine
which predominantly promotes SHP-2 binding. Increased phosphorylation of beta
catenin and FAK then promotes loosening of cell-cell adhesion and extension formation
at the leading edge of the wound. PECAM-1 is then both a necessary component and a
modulator of coordinated endothelial migration.

ITIM signaling questions

Further analysis of PECAM-1 ITIM mediated signaling is complicated by the
multiple roles played by SHP-2 in proliferative and migratory responses to growth factor
receptor signaling (Feng, 1999). Manipulation of overall cellular tyrosine phosphatase
activity or even SHP-2 activity is therefore not informative in dissecting this pathway. A
construct encoding a fusion protein consisting of the extracellular domain of PECAM-1
fused directly to the constitutively active tyrosine phosphatase domain of SHP-2 (Noda et
al., 2001) has been made for the purpose of addressing this question. This may yield
candidate SHP-2 substrate phosphoproteins, although it is unclear that a construct lacking
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the entire cytoplasmic domain would be targeted to the same membrane subdomains as
full length PECAM-1; additionally, proteins such as beta catenin that associate with the
PECAM-1 cytoplasmic domain may not be accessible to this construct A construct
comprising full-length PECAM-1 fused to a substrate-trapping mutant of the SHP-2
tyrosine phosphatase domain (Flint et al., 1997) may be useful to identify direct targets
by co-immunoprecipitation.
The role of the PECAM-1 ITIM in modulating VE-cadherin associated catenin
phosphorylation and the integrity of vascular adherens junctions remains to be elucidated.
Is alpha catenin lost from beta catenin-VE cadherin complexes when PECAM-1 ITIM
signaling is inhibited? Is plakoglobin also a substrate for PECAM-1 ITIM-mediated
dephosphorylation? Plakoglobin links VE-cadherin to vimentin, a component of the
intermediate filament cytoskeleton; in wounded endothelial monolayers, it is the first
component lost from the dissolving adherens junctions in mechanically wounded
endothelium (Lampugnani et al., 1995). Tyrosine phosphorylation o f plakoglobin in
histamine-stimulated endothelium is accompanied by loss of coupling of VE cadherin to
vimentin and thus intermediate filaments (Shasby et al., 2002). Not only may PECAM-1
ITIM mediated signaling modulate adherens junction stability; PECAM-1 itself binds
both beta catenin and plakoglobin (Ilan et al., 2000), and may itself be coupled to the
actin and/or intermediate filament cytoskeleton. The potential modulation of PECAM-1
and/or VE-cadherin-vimentin coupling via the phosphorylated ITIM domain remains to
be explored.
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Gaipha/Rho signaling questions

The evaluation of PECAM-1 modulation of heterotrimeric G protein and Rho
signaling pathway activities presented above has been performed using confluent
endothelial cells. These data evaluate signaling while cells are in a steady state, rather
than in reaction to some physiologic stimulus. In reality migration involves transient,
spatially appropriate activation of signaling pathways, such as the activation of ERK
signaling in response to FGF-2 at the migrating front of wound-healing endothelial cells
(Pintucci et al., 2002) and the transient suppression of Rho signaling by pl90RhoGAP at
the leading edge of a migrating cell upon engagement of alpha5betal integrins (Arthur
and Burridge, 2001). Raft localization of signaling molecules, including heterotrimeric G
protein alpha subunits, might also vary temporally both over the course of migration and
in response to specific chemotactic stimuli. It will be worthwhile to explore the kinetics
of signaling pathway activation in PECAM-1 deficient as compared to PECAM-1
expressing endothelial cells.
Much work remains to be done to elucidate the precise mechanisms of PECAM1-mediated coordination of Galpha signaling. Is the observed decrease in RhoGTP levels
in PECAM-1 deficient endothelium due only to increased pl90RhoGAP tyrosine
phosphorylation secondary to promiscuous activation of src via Galphai2, or is it also
mediated by decreased activation of PDZRhoGEF by Galphal3 (Fukuhara et al., 1999)?
Does PECAM-1 modulate raft recruitment of Galpha subunits directly, or through effects
on Galpha interacting proteins? Both cadherins and catenins have been found to localize
to caveolin positive rafts (Galbiati et al., 2000). Active, GTP-bound Galphal3 competes
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with beta catenin for VE cadherin binding (Meigs et al., 2001); competition by PECAM1 for beta catenin association could free VE cadherin to associate with activated
Galphal3, promoting the exchange of GDP for GTP and activating Rho signaling.
Caveolin-1 association inhibits Galpha subunit GTP loading (Li et al., 1995) and
consequently of downstream signaling. Does PECAM-1 modulate not only targeting to
lipid rafts, but also caveolin-1 association, of Galpha subunits?
The role of PECAM-1 in properly transmitting SIP mediated signaling
information may hold clues to the known phenotypes of the PECAM-1 knockout mouse.
Is the defect in angiogenesis during the chronic phase of foreign body inflammation
secondary to deficient SIP mediated signaling? In vitro tube formation assays, as well as
in v/vo assays of angiogenesis using pellets impregnated with SIP alone or in
combination with other growth factors, may help to address this question.
The possible role of PECAM-1 mediated Rho signaling in transmitting the
inhibitory of effect of high glucose on single cell motility of transforming endocardial
cushion cells has already been discussed. Further clarification is needed of the signaling
pathways involved in the endocardial cushion system. Experiments to confirm the
protective role of Rho inhibition are under way in this system. Further work will explore
the role of VEGF-mediated Rac activation in mediating migration of transforming
endocardial cells over the collagen I gel (see Figure 15b). Treatment with Nacetylcysteine to block Rac mediated production of H2 O2 should disinhibit low molecular
weight PTPase. The dephosphorylation of pl90RhoGAP would be expected block local
inhibition of Rho signaling, and should therefore block endocardial cell motility even in
the presence of supplemental VEGF.
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SIP increases transendothelial resistance, a measure of vascular junctional
integrity, in a pertussis-inhibitable, Rho-dependent manner (Garcia et al., 2001).
PECAM-1 null endothelium exhibits prolonged permeability in response to histamine,
and transmigration of T cells is enhanced across PECAM-1 null endothelium. This
vascular defect may in part contribute to the susceptibility of PECAM-1 null mice to
invasion of their central nervous system by leukocytes as a part of the pathogenesis of a
mouse model of multiple sclerosis (Graesser et al., 2002). Is this due in part to the
decreased responsiveness of the PECAM-1 deficient vasculature to the serum-derived
sphingolipids that promote the reestablishment of tight vascular junctions? In vitro
testing of SIP-mediated increases of transendothelial resistance of PECAM-1 deficient
versus wildtype vasculature could address this question.
Similarly, the bleeding time defect of PECAM-1 null mice is attributable to the
vasculature rather than to bone marrow derived components (Mahooti et al., 2000). High
concentrations of SIP are released from platelets during clotting, but successful stanching
of bleeding involves more than just platelet activation and thrombosis. The subjacent
endothelium must also contract to reveal the underlying thrombogenic collagen surface in
response to platelet-released factors such as thrombin (Cotran et al., 1994). Thrombin
mediates endothelial cell contraction through RhoGTP-mediated activation of
pl60ROCK, myosin light chain kinase, and consequently actin-myosin mediated
contractility (Essler et al., 1998). In the context of inflammation, histamine likewise
promotes a pl60ROCK-mediated increase in endothelial permeability (Wojciak-Stothard
et al., 2001). Preliminary studies indicate that both thrombin and histamine activate Rho
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to a significantly lower extent in PECAM-1 null as opposed to PECAM-1 reconstituted
endothelial cells (data not shown).
The thrombin receptor belongs to the seven-transmembrane heterotrimeric G
protein linked family of protease activated receptors (PARs) and promotes endothelial
cell migration and angiogenesis through pathways involving Rho signaling downstream
of Galphal3 (Maragoudakis et al., 2002; Richard et al., 2001). Histamine receptor
subtype HI, which promotes vascular permeability, is also a seven transmembrane
receptor, although unlike the thrombin receptor it is ligand activated and primarily signals
through Galphaq/11 (Leurs et al., 1995). Thus the role of PECAM-1 in modulating SIP
mediated wound healing migration may extend to modulation of signaling via Galpha
subunits downstream of multiple seven transmembrane receptors. Importantly, CXCRs,
seven-transmembrane receptors for cysteine-x-cysteine motif containing chemokines
including SDF-1 (CXCR4) (Salvucci et al., 2002) and interleukin-8 related cytokines
(CXCR1/2) (Belperio et al., 2000), play an important role in angiogenesis in the settings
of injury, inflammation and neoplasia. Further pursuit of the signaling pathways and
(patho)physiologic sequelae of PECAM-1 expression should prove fruitful for years to
come.

In vitro migration assays: how should they be interpreted?

Nondirected single cell motility, or chemokinesis, represents an increase in cell
movement in response to serum or cell derived growth factors; angiogenic growth factors
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such as VEGF and SIP induce not only an increase in this baseline cell movement, but
directional motility with respect to a concentration gradient (chemotaxis if the gradient is
in the liquid phase, haptotaxis if it is fixed to cell surfaces or to extracellular matrix).
Most developmental or physiologic cell movements in vivo occur in a directional maimer
in response to some chemotactic or haptotactic cue, with a balance between the degree of
increase in baseline cell motility and the degree to which that motility is strictly
directional. At one end of the spectrum of in vivo correlates to chemokinesis as opposed
to chemotaxis, for example, lies hepatocyte growth factor (HGF). HGF induces
scattering motility in vitro through activation of the Met tyrosine kinase receptor and
promotes the dissemination and invasive behavior of malignant carcinoma cells in
response to autocrine signaling (Danilkovitch-Miagkova and Zbar, 2002). At the
opposite end of the random versus directed single cell motility spectrum, neuronal cell
migration in vivo is exquisitely directionally guided through a combination of
chemotactic and haptotactic cues which tightly control Rho and Rac activation and hence
directional motility (Park et al., 2002b).
Coordinated wound healing migration necessarily involves directional movement,
as the wounding induces release of chemotactic factors at the leading edge and uncovers
haptotactic factors previously laid down by the endothelial monolayer. For example,
injury induces endothelial release of fibroblast growth factor-2 (FGF-2), which
contributes to the endothelial wound healing response in vitro (Pintucci et al., 2002;
Santiago et al., 1999). In vivo, denuded basement membrane promotes platelet
aggregation and release of multiple chemotactic factors including SIP, which also
promotes endothelial wound healing migration (Lee et al., 2000a). Finally, exposed
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extracellular matrix components such as fibronectin themselves provide strong
haptotactic cues to endothelial wound healing and angiogenesis (Kim et al., 2000).
PECAM-1 deficient endothelial cells perform poorly in the wound healing assay in vitro
and in vivo demonstrate poor angiogenesis during the chronic phase of foreign body
inflammation (Solowiej et al., 2002).
Although the single cell motility of PECAM-1 deficient endothelial cells is
dramatically increased with respect to PECAM-1 expressing cells, I would predict that
these cells would respond weakly if at all to a directional signal in assays of single cell
chemotaxis or haptotaxis. Indeed, I believe that the very property that allows these cells
to form multiple extensions and initiate motility in the absence of a directional signal,
their low level o f RhoGTP signaling at baseline, would perforce lower their sensitivity to
inputs that modulate directionality by transiently decreasing Rho signaling to allow for
extension formation at the leading edge (see Fig 15b). Thus, for example, a Transwell™
single cell motility assay of chemotaxis toward VEGF might reveal the same or even a
greater number of transmigrated PecamKO than PecamRC cells due to the chemokinetic
advantage of PecamKO cells; however the increase in transmigration with the addition of
VEGF to the bottom well would be expected to be dramatically greater in the case of the
PecamRC cells.

Does PECAM-1 signaling modulation have any real-world applicability?

104

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

A thorough understanding of the mechanics of PECAM-mediated modulation of
heterotrimeric G-protein mediated signaling in endothelial cells may yield viable tools
not only for the benchtop researcher but for the modulation of epidemiologically
important aspects of cardiovascular pathology. For example, PECAM-1 knockout mice
have significant defects in reestablishment of cell-cell junctional integrity following a
stimulus that increases permeability. Histamine induces a transient increase in
endothelial permeability; the duration of increased permeability is several times longer in
brain and dermal vasculature of PECAM-1 knockout mice and in PecamKO endothelial
cells in vitro (Graesser et al., 2002). This failure to reestablish cell-cell junctions
following what should be a transient increase in permeability may likewise underlie the
increased transmigration of T lymphocytes (Graesser et al., 2002) as well as
polymorphonuclear neutrophils (Solowiej et al., 2002) across PECAM-1 negative
endothelia. Further experiments will be required to determine how much of this defect is
due to a failure to dephosphoiylate beta catenin, and thus to reassemble stable actin
cytoskeleton-linked adherens junctions, due to a lack of PECAM-1 ITTM-mediated SHP2 activity at cell-cell borders. Stable transfectants of PecamKO endothelial cells
expressing ITIM-defective, full-length PECAM-1 should prove informative in this
regard. Therapeutic modulation of PECAM-1 ITIM phosphorylation may be achievable
with carefully developed anti-PECAM-1 antibodies or recombinant portions of the
PECAM-1 ectodomain.
Increased endothelial permeability contributes to the pathogenesis of a variety
major causes of morbidity and mortality such as atherosclerosis, chronic inflammation,
diabetic retinopathy, and sepsis. Heterotrimeric G protein mediated signaling and
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modulation of Rho activation through Galphal2/13 and Galphaq/11 (Sah et al., 2000) is
prominently involved in modulating endothelial permeability (van Nieuw Amerongen
and van Hinsbergh, 2001). The histamine receptors for example are G-protein coupled
seven transmembrane receptors (Leurs et al., 1995); the major receptor subtype involved
in modulating vascular permeability, HI, is linked to Galphaq/11. Thrombin signals
through Galphal2/13 to mediate Rho signaling and increased vascular permeability as
well as angiogenesis (Richard et ai., 2001). Lipophosphatidic acid (LPA), a product o f
low density lipoprotein (LDL) oxidation present in atherosclerotic plaques (Siess et al.,
1999), likewise stimulates endothelial cell permeability through heterotrimeric G protein
mediated modulation of Rho signaling. Sphingosine-1-phosphate, on the other hand,
promotes vascular maturation and decreased permeability through Edg-receptor
dependent signaling, including Rho activation (Garcia et al., 2001). It seems likely that
precise modulation of the timing, duration and localization of Rho signaling by
heterotrimeric G proteins is required to maintain a stable rather than a dysfunctional,
leaky vasculature. Since PECAM-1 appears to be capable of modulating the localization
of specific Galpha protein subunits to membrane microdomains, an analysis of the
particular region of the PECAM-1 cytoplasmic domain responsible for this localization
could prove to be quite valuable. Should an oligopeptide be found that is capable of
influencing the localization and thus the signaling properties of specific Galpha subunits,
its delivery to dysfunctional vascular beds may prove to be useful in modulating the
responsiveness of endothelia to permeability-inducing or atherogenic stimuli.
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Chapter 5: Materials and Methods

Antibodies

Rabbit polyclonal antibody to murine PECAM-1 extracellular domain (Sleet),
human PECAM-1 cytoplasmic domain (BooBoo), and to PECAM-1 ITIM
phosphotyrosines 663 or 686 (Lu et al., 1996; Pinter et al., 1997) were generated in our
laboratory and have been previously described. Monoclonal antibodies to extracellular
signal regulated kinase 2 (ERK2), phosphotyrosine, and SHP-2 and polyclonal antibody
to caveolin and paxillin phosphotyrosine 118 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Monoclonal antibodies to beta catenin, Racl, Rho and
focal adhesion kinase (FAK) and polyclonal antibodies to heterotrimeric G protein
subunits Galphai2 and Galphal3 were purchased from Transduction Laboratories (San
Diego, CA). Monoclonal antibodies to RhoGAP (Guanosine triphosphate Phosphatase
Activating Protein) p i90 and polyclonal antibodies to FAK phosphotyrosine 397 and
RasGAP pl20 were purchased from Upstate Biotechnologies (Lake Placid, NY). Antiphosphothreonine/tyrosine ERK polyclonal antibody was purchased from Cell Signaling
Technology (Beverly, MA). Monoclonal antibody to beta actin was purchased from
Sigma-Aldrich (St. Louis, MO). Monoclonal hamster antibody against murine PECAM1, and monoclonal rat antibody against murine vascular endothelial cadherin, for
fluorescence activated cell sorting (FACS) analysis were purchased from PharMingen
(San Diego, California, USA).
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Reagents

Rhodamine-phalloidin and methyl beta cyclodextrin was purchased from SigmaAldrich (St. Louis, MO). C. botulinum exoenzyme C3 (exo C3), pertussis toxin (PTX),
sphingosine-1 -phosphate (SIP) and Y27632 were purchased from CalbiochemNovabiochem (San Diego, CA). Complete Protease Inhibitor™ (CPI) was purchased
from Roche Diagnostics (Mannheim, Germany). Polypeptides, both phosphorylated and
nonphosphorylated, were synthesized by the Howard Hughes Medical Institute-Keck
Foundation Lab at Yale University. Sequences were: for the PECAM-1 ITIM tyrosine
663 sequence, PLN SDV QY (phospho) T EYQ VSS; and for the tyrosine 686 sequence,
KKD TET VY (phospho) S EVR KAV.

Constructs

Full-length human PECAM-1 in the mammalian expression vector pAPEX-1
(Alexion, New Haven, CT) and its Y663F mutant have been described (Lu et al., 1996).
An additional mutation at Y686F was made using the QuikChange™ Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer’s instructions
to produce an ITIM-defective construct. A myc-tagged truncated construct in pAPEX-1
lacks most of the ectodomain (Kim et al., 1998). The PECAM-1 cytoplasmic domain in a
glutathione-S-transferase (GST) fusion protein expression construct (pGEX2T,
Pharmacia, Piscataway NJ) (Lu et al., 1997) was also mutated at Y686F and at Y663F.
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pGEX2T-SHP-2 construct was a gift o f H. Ohnishi et aL(Ohnisbi et al., 1996); a
phosphatase-dead mutant (D425A) (Flint et al., 1997) was made using site-directed
mutagenesis.
The Rho binding domain of Rhotekin in pGEX2T (Pharmacia) was a gift of X.D.
Ren and M.A. Schwartz (Ren and Schwartz, 2000). A GST-fusion protein expression
construct of the Rac binding region of PAK, pGEX4T-l PAK70-106, was a gift of F.
Giancotti (Mettouchi et ai., 2001).
Myc-tagged SHP-2 and SHP-2 loss of function mutant C459S in pIRES-EGFP
(Clontech, Palo Alto, CA) were a gift of M. Kontaridis and A. Bennett. An SHP-2
mutant incapable of engaging its C-terminal SH2 domain (R138K) (Pluskey et al., 1995)
was made by site-directed mutagenesis. pCDNA3-VCAM mammalian expression
construct was made by subcloning the full-length cDNA purchased from Biogen
(Cambridge, MA).

Oligonucleotides

PECAM-1 antisense oligonucleotides: 5’ TCC TTC CAG GGA TGT GAT C 3’
for human PECAM-1 and control scrambled oligonucleotide 5’ TTC TAC CTC GCG
CGA TTT AC 3’ were gift of T. Condon at Isis™ Pharmaceuticals (Carlsbad, CA).
Mutagenic primers were: for PECAM-1 Y686F, 5’ GGA CAC AGA GAC AGT
G IC AGT GAA GTC CGG 3’ and its inverse; for PECAM-1 Y663F, 5’ CCT CTG AAC
TCA GAC GTG CAG TTC ACG GAA GTT CAA GTG TCC 3’ and its inverse; for
SHP-2 D425A, 5’ GGA CCT GGC CAG CCC ATG GCG TGC C 3’ and its inverse; for
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SHP-2 R138K, 5’ CAT GGT AGT TTT CTT GTA AAA GAG AGC CAG AGC CAC
CCT GG 3’ and its inverse.

Cell culture

Endothelioma cell line luEnd.PECAM-1.1 (PecamKO) was established by
retroviral transduction of primary endothelial cell culture with the polyoma virus middle
T-oncogene (Wagner and Risau, 1994; Wong et al., 2000). PecamKO cells retrovirally
transduced with full-length murine PECAM-1 cDNA to generate a PecamRC
(reconstituted) cell line (Graesser et al., 2002; Wong et al., 2000). Cells were cultured in
luEnd media [Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 10 mM HEPES pH 7.4,1% L-glutamine, 1% nonessential
amino acids, 1% pyruvate, 10,000 U/ml penicillin/ streptomycin, and 105M 2mercaptoethanol (GIBCO BRL)] and incubated at 37°C in 8% CO2 . Selection of
PECAM-1 expression on PecamRC cells was maintained with 1 pg/ml puromycin.
Human umbilical vein endothelial cells (HUVEC) were purchased from the Boyer
Center for Molecular Medicine Cell Culture Core (Yale Medical School) and were
cultured on gelatin in Ml 99 medium (Life Technologies) supplemented with 20% heatinactivated FBS, 50 mg/ml endothelial cell growth supplement, 50 mg/ml heparin, 10
mM HEPES, 2 mM L-glutamine and antibiotics. Bovine aortic endothelial cells
(BAECs) were cultured as previously described (Madri et al., 1988).
Hemangioendothelioma (Eoma) cells were obtained from Robert Auerbach (University of
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Wisconsin, Madison, WI) and were grown in complete DMEM supplemented with 10%
FBS and antibiotics (Obeso et al., 1990).

Immunostaining

Cells were incubated overnight on 8-chamber glass culture slides (Falcon,
Becton-Dickinson) that had been coated with fibronectin. Cells were fixed in Streck's
Tissue Fixative (STF, Streck Laboratories, La Vista, NE), permeabilized with 0.5%
Triton X-100 in TBS, and stained with rhodamine-phalloidin 1:200, anti-phosphopaxillin
1:500, anti-PECAM-1 1:100 or anti-SHP-2 1:100 followed by fluorescein or rhodamineconjugated secondary (Jackson Immunoresearch Labs, West Grove, Pennsylvania) at
1:200. After coverslipping with Antifade Mounting Media (Molecular Probes, Eugene,
OR) cells were photographed using a Carl Zeiss Research microscope (Gottingen,
Germany) and SPOT digital camera (Diagnostic Instruments Inc, Sterling Heights,
Michigan).

Transient transfections

Subconfluent PecamKO or PecamRC endothelial cells were transfected using
LipofectAMINE2000, Life Technologies (Grand Island, NY) according to the
manufacturer’s instructions. Briefly, cells were split 1:3 into 100 mm tissue culture
plastic dishes and cultured overnight. When they had reached 70-80% confluence they
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were transfected using 1 jig pIRES EGFP + 9 pg test DNA and 30 pi transfection
reagent. Expression was assessed using green fluorescence at 24 hours.
For antisense oligonucleotide transfections, passage three HUVEC at 70-80%
confluence were transfected using Lipofectin (Life Technologies) according to the
manufacturer’s instructions. PECAM-1 expression was assessed by western blotting at
24 or 48 hours by western blot.

Nondirected motility assay

8 pm pore size Transwells® (Coming Inc. Coming, NY) were coated overnight
with 12.5 pg/ml fibronectin (Madri et al., 1988) or type I collagen (Haas et al., 1998) and
blocked with 5% BSA as described. 100 pL of media was added to the top well and 500
pL to the bottom well. Endothelial cells were briefly trypsinized, washed twice in
endothelial media, and 100 pL of a 106cell/ml single cell suspension was added to the
top well. Lung endothelial cell transmigrations were done in luEnd media. HUVEC
transmigrations were done in HUVEC media lacking endothelial cell growth supplement
and with FBS decreased to 2%. After 2.5 hours of incubation at 37°C in 8% CO2 the
cells were fixed in STF, and stained with crystal violet. Cells on top of the filter were
removed with a cotton swab and cells on the bottom surface were quantitated as number
of cells transmigrated per high power field (20x objective, corresponding to an area of
approximately 5mm2).

Wound healing assay
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60 mm Falcon® petri dishes (Becton Dickinson, Franklin Lakes NJ) were coated
with fibronectin as above. Butanol-extracted fibronectin and BSA were used for
experiments involving SIP. Confluent PecamKO and PecamRC monolayers grown on
fibronectin-coated plates were scraped with a 15-well minigel comb leaving concentric
rings of cells, washed with PBS, and incubated 24 hours. HUVEC wound healing
migrations were on gelatin-coated plates. For SIP experiments, CS-FBS was prepared by
incubating 50 mL FBS with 5 g activated charcoal (Sigma) overnight at 4°C (Lee et al.,
1998). The CS-FBS was centrifuged (10 min at lOOOg) and filtered through a 0.22 pm
sterile Nalgene® filter (Sybron Corp, Rochester NY). Distance migrated was quantitated
by taking pictures at 0 and 24 hours with a Nikon Coolpix995 Digital Camera (Nikon
Corp., Tokyo Japan) on an Olympus IM light microscope (Melville, NY) and measuring
distance of wound edge from a mark on the bottom of the plate.

Quantitation of extension formation

104 cells/well were plated in a fibronectin-coated 24-well plate. Cells were fixed
in STF and stained with crystal violet, photographed as above, and quantitated using the
public domain NIH Image program (National Institutes of Health) to determine perimeter
and cell area. The theoretical radius (r) had the cell been a perfect circle was determined
according the formula r^meier = perimeter/27t and rarea= V(area/7t), and the ratio rpenmeter to
Tarea was used to determine deviation from circularity.
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Western blotting

Confluent monolayers of PecamRC and PecamKO cells were washed twice in
ice-cold PBS containing 1 mM orthovanadate, and scraped into lysis buffer (20 mM Tris
pH 7.5,100 mM NaCl, 10 mM EDTA, 1% Nonidet P-40,1% deoxycholate, 0.1% SDS,
50 mM sodium fluoride, 1 mM sodium orthovanadate, and CPI). Wound-healing BAECs
were lysed in 200 pi [50 mM Tris, pH 7.4,100 mM NaCl, 0.5 % Triton X-100, 0.5 %
sodium deoxycholate, a protease cocktail (CPI, Boehringer-Mannheim) and 0.2 mM
orthovanadate]. Lysates were centrifuged at 14,000# at 4 °C for 10 minutes, and
supernatant protein concentration was determined using the Bio-Rad Protein Assay (BioRad Laboratories, Hercules, CA) as directed. 20 pg protein were boiled with 4x sample
buffer (240 mM Tris pH 6.8,40% glycerol, 8% SDS, 0.002% bromophenol blue, 0.002%
B-mercaptoethanol).
Samples were separated by SDS PAGE, transferred to an Immobilon P
membrane, (Millipore, Bedford, MA), probed with anti-ERK 1:10,000, anti-phosphoERK
1:1000, anti-FAK 1:10,000 and anti-FAK PY397 1:2000, followed by horseradish
peroxidase conjugated goat anti-mouse or anti-rabbit IgG, (Promega, Madison, WI) and
developed using Chemiluminescent Reagent Plus (PerkinElmer Life Sciences, Boston,
MA). Blots were scanned on an Arcus II scanner (Agfa, Mortsel, Belgium) and
quantitated using BioMax ID software (Kodak, Rochester, NY).

Immunoprecipitation
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200 pg protein were pre-cleared with protein A/G-Sepharose (Santa Cruz); the
cleared supernatant was incubated with the appropriate antibody for one to two hours
turning end-over-end at 4°C, then precipitated with A/G-Sepharose. Beads were washed
three times in lysis buffer and boiled in 4x sample buffer. Samples were separated by
SDS-PAGE, transferred to an Immobilon P membrane, probed with anti beta catenin
1:10,000, anti-pl90 RhoGAP 1:5000, anti-pl20 RasGAP 1:5000, anti-SHP-2 or antiphosphotyrosinc 1:10,000, and developed and quantitated as above.

Triton X-100 fractionation

Triton X-100-soluble and insoluble fractions were prepared as described in
(Rajasekaran et al., 2001). Briefly, cells were scraped into 200 pi lysis buffer (50 mM
NaCl, 10 mM PIPES pH 6.8,3 mM MgCh, 0.5% Triton X-100,300 mM sucrose, 1 mM
PMSF, 100 U/ml DNAse) for 10 min at 4°C, then centrifuged at 4°C for 30 min at
14,000 rpm. Pellet and supernatant fractions were boiled in 4x sample buffer prior to
separation by SDS-PAGE, immunoblotting, and probing with anti-beta actin 1:10,000,
anti-FAK 1:10,000, or anti-SHP-2.

Raft fractionation

Sucrose density gradient lipid raft fractionation was carried out in a
detergent-free sodium bicarbonate buffer essentially as described by (Song et al., 1996).
Briefly, confluent endothelial cells were scraped into lysis buffer (500 mM sodium
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bicarbonate) and sonicated. 85% sucrose in MBB (25 mM MES, pH 6.5,150 mM NaCl,
and 250 mM sodium bicarbonate) was added to bring the sample to 42.5% sucrose. The
two mL sample was placed in an ultracentrifuge tube on ice for 4 hours, then layered with
8 mL o f 30% sucrose in MBB followed by 2 mL 5% sucrose in MBB were layered to
make a discontinuous gradient.
The sample was centrifuged at 39,000 rpm for 18 hr at 4°C in an SW41
rotor (Beckman Instruments, Palo Alto, CA), at which time an opalescent band
representing the caveolin-positive raft fraction was visible at the 30%/5% sucrose
interface. One mL fractions were carefully pipetted, and 20 pL samples boiled in 4x
sample buffer for analysis, separated by SDS-PAGE and transferred to an Immobilon P
filter. Blots were probed with anti-PECAM-1, anti-SHP-2, antiphosphotyrosine, anticaveolin, or anti-beta actin at 1:10,000 or anti-Galphai2 or anti-Galphal3 at 1:250 and
developed and quantitated as above.

Recombinant protein production

GST-PECAM-1 cytoplasmic domain was expressed in protease deficient BL21
bacteria (Pharmacia) induced with 0.5 mM isopropyl-fi-D-thiogalactoside (Sigma) for 3
hours at 37°C. Bacteria were lysed with Bacterial Protein Extraction Reagent (Pierce)
and Complete Protease Inhibitor (CPI) (Boehringer Mannheim). After spinning 30 min
at 14,000g at 4°C, the bacterial lysate supernatant was incubated with a 50% slurry of
glutathione agarose beads (Sigma) to pull out the GST fusion protein, and washed 5 times
in TBS + 1 mM ethylene diamene tetraacetic acid to eliminate bacterial proteins.
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Tyrosine phosphorylated GST-PECAM-1 was produced as directed in TKX1 bacteria
(Stratagene) and phosphorylation confirmed by western blotting with phosphospecific
antibodies to ITIM phosphotyrosines 663 and 686 at 1:5000 as described.
Concentration was determined using a standard curve of bovine serum albumin
(Pierce) after SDS-polyacrylamide gel electropheresis (PAGE) and Coomassie staining.
GST-SHP-2 was produced essentially as described (Dechert et al., 1994), but in BL21
bacteria (Pharmacia) and at 28°C. Thrombin cleavage of recombinant SHP-2 from its
GST tag was carried out as described (Dechert et al., 1994); concentrations were
determined as with Bio-Rad Protein Assay (Hercules, CA).

Recombinant SHP-2 pulldowns

10 pg of glutathione-agarose-bound GST-PECAM-1 was combined with 5 pg
recombinant SHP-2 in 500 pi Pulldown Buffer (50 mM Tris, pH 7.4,100 mM NaCl, 0.5
% Tween-20,10 mM (3-mercaptoethanol) and rotated for 30 min at 4°C. The glutathione
agarose beads with bound GST-PECAM-1 and any associated SHP-2 were washed in
cold Pulldown Buffer. Samples were separated by SDS PAGE, western blotted as
described, probed with anti-SHP-2 1:10,000 or anti-PECAM-1 1:10,000, and developed
and quantitated as described.

RhoGTP and RacGTP pulldown assays
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GST-Rho binding domain was expressed and purified using glutathione-agarose
beads (Sigma-Aldrich) as described (Ren and Schwartz, 2000). GST-p21 Activated
Kinase (PAK) Rac binding domain was expressed and purified as described (Royal et al.,
2000). Freshly confluent PecamRC or PecamKO cells grown on fibronectin-coated 100
mm plates were lysed, 20 pL lysate set aside for normalization, and RhoGTP or RacGTP
pulled down using glutathione-agarose-bound GST-Rho binding domain or GST-PAK
Rac binding domain as described (Ren and Schwartz, 2000; Royal et al., 2000). Samples
were separated by SDS PAGE, transferred to an Immobilon P membrane, probed with
anti-Rho 1:100 or anti-Rac 1:100 and developed and quantitated as above.

Recombinant SHP-2 phosphatase assays

To assess activation of recombinant SHP-2 by GST-PECAM-1,3 pg bead-bound
GST-PECAM-1 and 2 pg recombinant SHP-2 was suspended in 45 pi Phosphatase
Buffer (50 mM sodium acetate, pH 5.3,50 mM NaCl, 10 mM dithiothreitol) in 96-well
plates (Falcon); at t = O’ 5 pi 500 mM /Miitrophenyl phosphate (pNPP) were added and
the mixture shaken 10 min (adapted from (Ohnishi et al., 1996)). A Wallac Victor
Multilabel Counter attached to a PC laptop was used to record absorbance at 405 nm.

Immunoprecipitated SHP-2 phosphatase activity

Phosphatase activity of immunoprecipitated SHP-2 was assessed essentially as
described (Tang et al., 2000). Briefly, cells were treated with pervanadate prior to lysis
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and SHP-2 was immunoprecipitated in the presence of orthovanadate on ice.
Orthovanadate was washed out to disinhibit phosphatase activity and dephosphorylation
allowed to proceed for 0 or 20 minutes at 25°C prior to quenching with lOmM
orthovanadate. Tyrosine phosphorylation of SHP-2-associated proteins was evaluated by
western blotting.
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